<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73223</article-id><article-id pub-id-type="doi">10.7554/eLife.73223</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-253035"><name><surname>Hwang</surname><given-names>Justin H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1686-7103</contrib-id><email>jhwang@umn.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-253036"><name><surname>Arafeh</surname><given-names>Rand</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-253037"><name><surname>Seo</surname><given-names>Ji-Heui</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7280-3334</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253038"><name><surname>Baca</surname><given-names>Sylvan C</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253039"><name><surname>Ludwig</surname><given-names>Megan</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253040"><name><surname>Arnoff</surname><given-names>Taylor E</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-277138"><name><surname>Sawyer</surname><given-names>Lydia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253041"><name><surname>Richter</surname><given-names>Camden</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-277137"><name><surname>Tape</surname><given-names>Sydney</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253042"><name><surname>Bergom</surname><given-names>Hannah E</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253043"><name><surname>McSweeney</surname><given-names>Sean</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7682-2073</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253044"><name><surname>Rennhack</surname><given-names>Jonathan P</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253045"><name><surname>Klingenberg</surname><given-names>Sarah A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253046"><name><surname>Cheung</surname><given-names>Alexander TM</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253047"><name><surname>Kwon</surname><given-names>Jason</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-253048"><name><surname>So</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-277307"><name><surname>Kregel</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-163014"><name><surname>Van Allen</surname><given-names>Eliezer M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund11"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-141976"><name><surname>Drake</surname><given-names>Justin M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-86476"><name><surname>Freedman</surname><given-names>Matthew L</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-5558"><name><surname>Hahn</surname><given-names>William C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2840-9791</contrib-id><email>william_hahn@dfci.harvard.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Masonic Cancer Center, University of Minnesota-Twin Cities</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Department of Medicine, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jzgtq86</institution-id><institution>Department of Medical Oncology, Dana-Farber Cancer Institute</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05a0ya142</institution-id><institution>Broad Institute of MIT and Harvard, Cambridge</institution></institution-wrap><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03vek6s52</institution-id><institution>Harvard Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Department of Pharmacology, University of Minnesota-Twin Cities</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gq02987</institution-id><institution>Warren Alpert Medical School of Brown University</institution></institution-wrap><addr-line><named-content content-type="city">Providence</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0190ak572</institution-id><institution>Grossman School of Medicine, New York University</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04b6x2g63</institution-id><institution>Department of Cancer Biology, Loyola University Chicago</institution></institution-wrap><addr-line><named-content content-type="city">Maywood</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Department of Pharmacology and Urology, University of Minnesota</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sawyers</surname><given-names>Charles L</given-names></name><role>Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cheah</surname><given-names>Kathryn Song Eng</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02zhqgq86</institution-id><institution>University of Hong Kong</institution></institution-wrap><country>Hong Kong</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors Co-first Authors to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>12</day><month>05</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e73223</elocation-id><history><date date-type="received" iso-8601-date="2021-08-20"><day>20</day><month>08</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-05-11"><day>11</day><month>05</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-08-18"><day>18</day><month>08</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.08.18.456892"/></event></pub-history><permissions><copyright-statement>© 2022, Hwang, Arafeh, Seo et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Hwang, Arafeh, Seo et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73223-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-73223-figures-v2.pdf"/><abstract><p>Metastatic castration-resistant prostate cancers (mCRPCs) are treated with therapies that antagonize the androgen receptor (AR). Nearly all patients develop resistance to AR-targeted therapies (ARTs). Our previous work identified CREB5 as an upregulated target gene in human mCRPC that promoted resistance to all clinically approved ART. The mechanisms by which CREB5 promotes progression of mCRPC or other cancers remains elusive. Integrating ChIP-seq and rapid immunoprecipitation and mass spectroscopy of endogenous proteins, we report that cells overexpressing CREB5 demonstrate extensive reprogramming of nuclear protein–protein interactions in response to the ART agent enzalutamide. Specifically, CREB5 physically interacts with AR, the pioneering actor FOXA1, and other known co-factors of AR and FOXA1 at transcription regulatory elements recently found to be active in mCRPC patients. We identified a subset of CREB5/FOXA1 co-interacting nuclear factors that have critical functions for AR transcription (GRHL2, HOXB13) while others (TBX3, NFIC) regulated cell viability and ART resistance and were amplified or overexpressed in mCRPC. Upon examining the nuclear protein interactions and the impact of CREB5 expression on the mCRPC patient transcriptome, we found that CREB5 was associated with Wnt signaling and epithelial to mesenchymal transitions, implicating these pathways in CREB5/FOXA1-mediated ART resistance. Overall, these observations define the molecular interactions among CREB5, FOXA1, and pathways that promote ART resistance.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>CREB5</kwd><kwd>prostate cancer</kwd><kwd>transcription reprogramming</kwd><kwd>therapy resistance</kwd><kwd>FOXA1</kwd><kwd>RIME</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007249</institution-id><institution>University of Minnesota</institution></institution-wrap></funding-source><award-id>Start up funds</award-id><principal-award-recipient><name><surname>Hwang</surname><given-names>Justin H</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U01 CA176058</award-id><principal-award-recipient><name><surname>Hahn</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U01 CA233100</award-id><principal-award-recipient><name><surname>Van Allen</surname><given-names>Eliezer M</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Kureit Cancer Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Baca</surname><given-names>Sylvan C</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001735</institution-id><institution>Weizmann Institute of Science</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Arafeh</surname><given-names>Rand</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Ray of Light</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hwang</surname><given-names>Justin H</given-names></name><name><surname>Bergom</surname><given-names>Hannah E</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>University of Minnesota. Targets of Cancer Training program grant T32 CA009138T32</institution></institution-wrap></funding-source><award-id>CA009138</award-id><principal-award-recipient><name><surname>Ludwig</surname><given-names>Megan</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>American Cancer Society-AstraZeneca</institution></institution-wrap></funding-source><award-id>PF-16-142-01-TBE</award-id><principal-award-recipient><name><surname>Hwang</surname><given-names>Justin H</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>Young Investigator Award from the American Society of Clinical Oncologists (ASCO)</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Baca</surname><given-names>Sylvan C</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001797</institution-id><institution>PhRMA Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Baca</surname><given-names>Sylvan C</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution>Mark Foundation Emerging Leader Award</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Van Allen</surname><given-names>Eliezer M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A comprehensive molecular interrogation of CREB5 interactions identified changes in protein and chromatin interactions of FOXA1 that promoted therapy resistance in prostate cancer cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The androgen receptor (AR) plays a fundamental role in the development and function of the prostate. AR transcriptional activity is required for the initiation and progression of prostate cancer and remains critical in metastatic castration-resistant prostate cancer (mCRPC) (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Armenia et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Grasso et al., 2012</xref>; <xref ref-type="bibr" rid="bib28">He et al., 2021</xref>; <xref ref-type="bibr" rid="bib60">Robinson et al., 2015</xref>). The standard of care for patients with mCRPC is androgen deprivation therapy (ADT) and AR-targeted therapies (ARTs). While ADT and ART initially induce responses and lengthen the survival of mCRPC patients, intrinsic or acquired resistance continues to be a substantial clinical obstacle. With limited treatment options, better mechanistic understanding of the targets that drive resistant disease is urgently needed.</p><p>Several lines of evidence indicate that mCRPC may acquire resistance to ART through multiple mechanisms. Recent studies of mCRPC patients resistant to second-generation ART and ADT have identified that a subset of the resistant mCRPC harbor AR genomic alterations through mutations, copy number gain, enhancer amplification, as well as increased resistant transcript variants (ARV7) (<xref ref-type="bibr" rid="bib11">Bubley and Balk, 2017</xref>; <xref ref-type="bibr" rid="bib30">Henzler et al., 2016</xref>; <xref ref-type="bibr" rid="bib66">Takeda et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Viswanathan et al., 2018</xref>). Other clinical and functional studies together demonstrate that resistance also occurs through mechanisms, including upregulation of cell cycle genes (<xref ref-type="bibr" rid="bib14">Comstock et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Han et al., 2017</xref>) and/or the proto-oncogene MYC (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>; <xref ref-type="bibr" rid="bib5">Armenia et al., 2018</xref>; <xref ref-type="bibr" rid="bib8">Bernard et al., 2003</xref>; <xref ref-type="bibr" rid="bib25">Grasso et al., 2012</xref>; <xref ref-type="bibr" rid="bib60">Robinson et al., 2015</xref>; <xref ref-type="bibr" rid="bib63">Sharma et al., 2013</xref>). In addition, selective activation of pathways such as epithelial to mesenchymal transition (EMT), TGFβ and Wnt has been recently identified from profiling mCRPC patient become resistant to second-generation ART or ADT (<xref ref-type="bibr" rid="bib3">Alumkal et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">He et al., 2021</xref>).</p><p>Recent mechanistic studies have begun to elucidate how dysregulated epigenomic and transcriptomic processes drive disease pathogenesis and progression. AR activity in prostate tissue is regulated by AR co-factors such as HOXB13 and FOXA1 at AR binding sites (ARBs) (<xref ref-type="bibr" rid="bib56">Pomerantz et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Pomerantz et al., 2020</xref>). ChIP-seq experiments have demonstrated that FOXA1, a co-factor with both pioneering and transcription functions, binds to distinct sites and has different protein interactions that is dependent on the disease stage and pathological phenotype (<xref ref-type="bibr" rid="bib6">Baca et al., 2021</xref>; <xref ref-type="bibr" rid="bib56">Pomerantz et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Pomerantz et al., 2020</xref>). Recent studies indicate that genomic alterations of <italic>FOXA1</italic> promote ART resistance (<xref ref-type="bibr" rid="bib2">Adams et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Baca et al., 2021</xref>; <xref ref-type="bibr" rid="bib54">Parolia et al., 2019</xref>; <xref ref-type="bibr" rid="bib61">Shah and Brown, 2019</xref>). We have shown that FOXA1 function remains functionally relevant even as mCRPC differentiate into aggressive variants that no longer require AR signaling, such as neuroendocrine prostate cancer (<xref ref-type="bibr" rid="bib6">Baca et al., 2021</xref>). We have previously demonstrated that the transcriptional factor cAMP-responsive element binding protein 5 (C<italic>REB5</italic>) promoted resistance to FDA-approved ART, enzalutamide, darolutamide and apalutamide (<xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>). CREB5 has also been associated with progression of cancers, including ovarian, colorectal, and breast (<xref ref-type="bibr" rid="bib9">Bhardwaj et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">He et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Molnár et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Qi and Ding, 2014</xref>). However, the molecular mechanisms by which CREB5 promotes resistance in mCRPC or general tumorigenesis remains unclear.</p><p>Here, we utilized ChIP-seq and rapid immunoprecipitation and mass spectrometry of endogenous proteins (RIME) experiments to resolve the CREB5-associated transcriptional targets and molecular interactions. These CREB5 transcriptional co-factors are potential therapeutic targets to perturb CREB5 signaling in cancers that upregulate its activity.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>CREB5 drives a resistance response to enzalutamide and androgen deprivation</title><p>We previously performed a large-scale screen to identify genes involved in ADT and ART resistance through overexpression of 17,255 open reading frames (ORFs) in LNCaP cells, an AR-dependent prostate cancer cell line (<xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>). We and others functionally validated several genes that drive ADT/ART resistance (FGFs, CDK4/6, MDM4, CREB5) in cell lines or mCRPC patients (<xref ref-type="bibr" rid="bib10">Bluemn et al., 2017</xref>; <xref ref-type="bibr" rid="bib14">Comstock et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Elmarakeby et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Han et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>). Here, we sought to interrogate the molecular mechanisms specifically associated with resistance to ADT and the clinically used ART, enzalutamide. Specifically, we identified ORFs that when overexpressed only promoted cell survival in the presence of ADT/ART and not in standard cultures. Upon re-examining the data, we found that unlike in ADT/ART, overexpression of CREB5 reduced viability (Z = –1.3) in standard cultures (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The Z-scores, which represent relative proliferation effects compared to all 17,255 ORFs, exhibited robust differentials when comparing the treated arm in comparison to the control arm (Z = +14.5 and –1.3). This observation contrasted to other genes that mediate resistance to ART, such as CDK4 or CDK6, which promoted cell fitness regardless of treatment conditions. At genome scale, many ORFs had preferential fitness effects when considering the differential Z-score of the treated and standard conditions. Among ORFs, CREB5 had the greatest differential viability effect after low androgen and enzalutamide treatment (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, Table 1). Overall, these observations prompted us to pursue a deeper interrogation of binding properties of CREB5 to understand specific molecular interactions that promote resistance to ART.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>CREB5 overexpression and nuclear interactions that are reprogrammed upon androgen receptor-targeted therapy (ART) treatments.</title><p>(<bold>A</bold>) Analysis of enzalutamide resistance genes in LNCaP cells based on a genome-scale screen, including 17,255 open reading frames (ORFs). Z-scores are displayed for the experimental arms conducted in either standard culture (FCS, x-axis) or treatment (enzalutamide +CSS, y-axis) conditions. CREB5 and other enzalutamide -specific hits (Z &gt; 3) and their proliferation scores are highlighted in red. (<bold>B</bold>) A model that depicts changes in chromatin -associated interactions of CREB5 that occur post enzalutamide treatment. Bottom,: CREB5 ChIP-seq data is presented in accordance to three categories of CREB5 binding behavior. Categories are grouped by significant changes by enzalutamide treatments. (<bold>C</bold>) GIGGLE analyses predicts transcription factors that are CREB5-bound based on the ChIP-seq experiments as categorized in B. (<bold>D</bold>) Rapid immunoprecipitation and mass spectroscopy of endogenous proteins (RIME) experiments were performed to identify CREB5 interaction profiles in control or enzalutamide -treated cultures. The common proteins identified by both RIME and GIGGLE are highlighted for the retained and gained groups.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>LNCaP cells overexpressing CREB5 or luciferase negative control (LUC) were transduced with lentivirus with shRNAs that target a GFP sequence or three distinct regions of androgen receptor (AR).</title><p>Cell viability was determined with standard error of the mean displayed (left). The degree of AR suppression is shown in immunoblots (right). V5 indicates expression of CREB5 or luciferase and tubulin is a loading control.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Immunoblots were used to detect expression of V5-tagged CREB5 or luciferase in the indicated samples for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig1-figsupp1-data1-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>The area highlighted was used to develop the figure for V5-tagged CREB5 or luciferase in the indicated samples for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig1-figsupp1-data2-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata3"><label>Figure 1—figure supplement 1—source data 3.</label><caption><title>Immunoblots were used to detect expression of androgen receptor (AR) in the indicated samples for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig1-figsupp1-data3-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata4"><label>Figure 1—figure supplement 1—source data 4.</label><caption><title>The area highlighted was used to develop the figure for androgen receptor (AR) in the indicated samples for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig1-figsupp1-data4-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata5"><label>Figure 1—figure supplement 1—source data 5.</label><caption><title>Immunoblots were used to detect expression of tubulin in the indicated samples for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig1-figsupp1-data5-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata6"><label>Figure 1—figure supplement 1—source data 6.</label><caption><title>The area highlighted was used to develop the figure for tubulin in the indicated samples for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig1-figsupp1-data6-v2.tif"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Dynamic CREB5 nuclear interactions are associated with the ART resistance response</title><p>We next determined the CREB5 cistrome as well as other regulatory proteins critical to the ART-resistant phenotype by identifying features that were either ‘retained’ or ‘gained’ upon ART treatments. In LNCaP cells overexpressing V5-tagged CREB5 or luciferase and cultured in either standard media or media containing enzalutamide, we analyzed differential interactions of CREB5 at regulatory elements through ChIP-seq or with other proteins through RIME. We first examined CREB5 binding sites pre- and post-enzalutamide treatments by performing CREB5 ChIP-seq. CREB5 overexpression induced a robust differential phenotype (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), in which lost (n = 5392), retained (n = 12,432), or gained (n = 12,144) CREB5 binding sites were tallied in the enzalutamide condition compared to the pretreatment condition. To nominate other candidate <italic>trans</italic>-acting factors that bind within the three defined categories, we used the GIGGLE, an analytical approach that compares collection of sequences from ChIP-seq experiments with over 10,000 experiments from the ENCODE ChIP-seq database and nominates the transcription factors with highly similar binding profiles (<xref ref-type="bibr" rid="bib42">Layer et al., 2018</xref>). We observed that the elements in which CREB5 retained or gained sites were statistically significantly enriched of other nuclear proteins in which ChIP-seq had been performed in prostate cancer cell lines. This included binding elements (AR, FOXA1, HOXB13) that we previously demonstrated through ChIP-seq experiments (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In addition, we also identify that retained or gained sequences nominated well-studied regulators or co-factors of AR such as GRHL2 (<xref ref-type="bibr" rid="bib53">Paltoglou et al., 2017</xref>), EP300 (<xref ref-type="bibr" rid="bib70">Yu et al., 2020</xref>), and SMARCA4 (<xref ref-type="bibr" rid="bib41">Launonen et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Marshall et al., 2003</xref>). In confirmation of previous findings, the genetic ablation of AR or FOXA1 reduced viability of CREB5-overexpressing cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>). These observations suggested that CREB5 bound critical regulators of prostate cancer biology to drive ART resistance.</p><p>RIME has been used as a tool to study transcription co-factors interactions in hormone-regulated cancer cells (<xref ref-type="bibr" rid="bib23">Glont et al., 2019</xref>; <xref ref-type="bibr" rid="bib47">Mohammed et al., 2016</xref>). To build upon the predictions of CREB5 binding by GIGGLE, we directly examined CREB5 nuclear interactions via RIME. As part of the RIME analysis, we included only the unique peptides that bound CREB5 after subtraction of all proteins precipitated by the V5 antibody or luciferase in cell lysates (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, Table 2). When we compared the analyzed RIME binding profiles of the control to the enzalutamide-treated conditions, analogous to the ChIP-seq experiments, we found the CREB5-bound unique peptides also segregated into lost (n = 77), retained (n = 222), and gained groups (n = 207) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). To consider key factors in the retained or gained groups that associate with resistance, we integrated the results derived from GIGGLE and RIME. From this, we found both approaches nominated known AR interactions (EP300, FOXA1, and GRHL2). Overall, these parallel approaches demonstrate that CREB5 binding dynamically responds to ART treatment. Moreover, the retained or gained RIME interactions indicate CREB5 may interact with distinct sets of co-factors, some of which are AR associated, to promote ART resistance.</p></sec><sec id="s2-3"><title>CREB5-FOXA1 interactions converge in ART resistance</title><p>In LNCaP cells, we comprehensively compared CREB5 and FOXA1 protein interactions using RIME. In prior work in LNCaP cells, we found that overexpressing CREB3, a related CREB family member, conferred significantly weaker resistance to enzalutamide, and therefore serves as a useful control to understand CREB5 functions in resistance (<xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>). We used RIME to target overexpressed V5-tagged CREB5, luciferase, or CREB3 upon treating cells with enzalutamide. We optimized experimental conditions to consistently observe unique peptides representing CREB5, CREB3, and FOXA1. On average, we detected 8, 23, and 14 unique peptides that respectively mapped to CREB5, CREB3, and FOXA1 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, Table 3). RIME interaction profiles were subsequently constructed for each targeted protein based on the visualization of the counts of all detected unique peptides that were bound. The overall RIME profiles of CREB5 and FOXA1 were compared and exhibited a positive correlation (<italic>R</italic> = 0.394), while those of CREB3 with either CREB5 or FOXA1 lacked correlation (<italic>R</italic> = 0.0332, –0.0498) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). At the peptide level, we found that CREB5 and FOXA1 shared a total of 504 protein interactions at chromatin, and of these 504, 335 did not interact with CREB3. While almost three times the number of CREB3 peptides were detected relative to CREB5, CREB3 and FOXA1 shared only 83 unique interactions (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). These observations nominated CREB5/FOXA1-specific protein–protein interactions.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>CREB5 and FOXA1 share chromatin-associated functions in metastatic castration-resistant prostate cancer (mCRPC) based on binding sequences and rapid immunoprecipitation and mass spectroscopy of endogenous proteins (RIME) interaction profiles.</title><p>(<bold>A</bold>) RIME analysis depicting the interaction profiles of FOXA1 (greay), CREB5 (red), and CREB3 (blue). Proteins that interact with FOXA1 and CREB5 are also shown. The Pearson correlation coefficients (R) are shownn. (<bold>B</bold>) Venn diagram depicting unique peptide interactions that are either independent or shared between CREB5 (red), CREB3 (blue), and FOXA1 (greay). Peptides identified to be induced by enzalutamide are highlighted as Retained/Gained. (<bold>C</bold>) ChIP-seq experiments were used to examine CREB5 and FOXA1 interactions in LNCaP cells with or without enzalutamide treatments. The Venn diagram depicts total binding sites in each condition and the overlapping sites and percentage of shared transcription regulatory elements. (<bold>D</bold>) CREB5 -bound sites are analyzed and represented as AR binding sites (ARBS) observed in clinical samples. This includes ARBS exclusive in normal (NARBS), tumor (TARBS), mCRPC (metARBS), all tissues (UARBS), as well as all non -ARBS (OTHER). E. CREB5 -bound ARBs are further classified and depicted as % of FOXA1 sites observed in mCRPC (y-axis). The colors represent the overall percentage of FOXA1 sites while the black represents non -FOXA1 sites.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig2-v2.tif"/></fig><p>As an orthogonal approach to RIME, we sought to examine ChIP-seq interactions of CREB5-FOXA1. We first examined the overlap of CREB5 and FOXA1 at transcription regulatory elements with and without ART. By analyzing ChIP-seq experiments that targeted either CREB5 or FOXA1, we found that regardless of ART, CREB5 and FOXA1 shared a strong degree of interactions as more than 90% of CREB5-bound sites were FOXA1 bound (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Pomerantz et al. have recently demonstrated that AR binding sites are reprogrammed during tumorigenesis and progression (<xref ref-type="bibr" rid="bib56">Pomerantz et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Pomerantz et al., 2020</xref>). Since CREB5 promoted ART-resistant activity, we anticipated CREB5 interactions at ARBs would be enriched in tumor-specific binding sites. When considering the subset of ARBs specific to progression, CREB5 indeed bound ARBs in prostate cancer (12.7%) or mCRPC (8.6%) tissue at higher rates as compared to normal prostate ARBs (0.2%) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Unlike ARBs, FOXA1 binding was less dynamic and the binding sites were relatively ubiquitous in prostate tissue. Almost all CREB5-bound sites were also observed in mCRPCs and were FOXA1 bound (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Taken together these observations demonstrate that CREB5 and FOXA1 engage a similar subset of proteins in cells with ART resistance and these interactions are enriched at ARBs or FOXA1 binding sites in mCRPC.</p></sec><sec id="s2-4"><title>CREB5-interacting co-factors are associated with ART resistance</title><p>To define which CREB5-specific interactions are required to drive ART resistance, we used CREB5 mutants to interrogate these interactions. Based on sequence alignment, the B-Zip and L-Zip domains are highly homologous in CREB and ATF family members (<xref ref-type="fig" rid="fig3">Figure 3A</xref>) and regulate binding to DNA- and CREB co-factors (<xref ref-type="bibr" rid="bib17">Dwarki et al., 1990</xref>; <xref ref-type="bibr" rid="bib45">Luo et al., 2012</xref>). Within the B-Zip and L-Zip domains, several leucine residues regulate transcriptional activity and heterodimerization with the transcription factors JUN and FOS in vitro (<xref ref-type="bibr" rid="bib20">Fuchs and Ronai, 1999</xref>; <xref ref-type="bibr" rid="bib52">Nomura et al., 1993</xref>). We engineered CREB5 point mutants that would emulate these structural perturbations by disrupting binding at chromatin (R396E), CRTCs (K405A and K406A), and JUN/FOS (L431P and L434P). We expressed these CREB5 variants in LNCaP cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>) and found that despite robust expression of L431P and L434P CREB5, cells expressing these mutants proliferated similarly to cells expressing luciferase controls in cell doubling assays performed in low androgen media containing enzalutamide (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), indicating L431P and L434P CREB5 lacked interactions critical for ART resistance.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>A loss of resistant CREB5 mutant was identified and determines transcription co-regulators associated with androgen receptor-targeted therapy (ART)-resistant proliferation.</title><p>(<bold>A</bold>) Alignment of CREB5 sequence with ATF2, ATF7, and CREB3, highlighting the DNA binding domains (blue), CRCT2 binding domains (red), and JUN/ATF binding domains (yellow). (<bold>B</bold>) Population doubling (y-axis) of LNCaP cells overexpressing wild-type CREB5 variants (red), CREB5 JUN/FOS-binding mutants (purple), and a luciferase negative control (green) in 10 μM enzalutamide. V5 expression represents V5-tagged CREB5 protein levels. Actin is a loading control. (<bold>C</bold>) Rapid immunoprecipitation and mass spectroscopy of endogenous proteins (RIME) analysis depicting the interaction profiles of wild-type CREB5 (red), CREB5 L434P (orange), and CREB3 (blue). CREB5 interactions that were reduced, retained, or gained upon enzalutamide treatments are depicted. The Pearson correlation coefficients (R) are shown. (<bold>D</bold>) A heatmap depicts the RIME interactions of luciferase control, wild-type CREB5, L434P CREB5, and CREB3. Several canonical AR co-factors (AR, FOXA1, HOXB13) interact with both CREB5 and CREB5 L434P and are shown.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Immunoblots were used to detect expression of V5-tagged CREB5 or luciferase in the indicated samples for <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig3-data1-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>The area highlighted was used to develop the figure for V5-tagged CREB5 or luciferase in the indicated samples for <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig3-data2-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Immunoblots were used to detect expression of actin in the indicated samples for <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig3-data3-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>The area highlighted was used to develop the figure for actin in the indicated samples for <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig3-data4-v2.tif"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig3-v2.tif"/></fig><p>To identify functional interactions specific to wild-type CREB5, we performed RIME in LNCaP cells overexpressing V5-tagged CREB5, CREB5 L434P, or luciferase (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, Table 4). At approximately the same average peptide counts of CREB5 (8) and L434 CREB5 (7.5), we found a striking correlation between the interaction profiles of CREB5 and CREB5 L434P (<italic>R</italic> = 0.834). This observation indicated that this CREB5 mutant binds the same proteins as the L434P mutant. In parallel, we failed to find a correlation between CREB3 and wild-type CREB5 (<italic>R</italic> = −0.0581) (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). The limited changes in the L434P CREB5 RIME profile highlighted a subset of differential protein interactions associated with the ART-resistant phenotype. When examining the interactions of wild-type and L434P CREB5, we found smaller differences between AR, FOXA1, and HOXB13 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Outside of AR co-factors, we detected unique peptide signals at comparable levels with AR, FOXA1, and HOXB13, including NFIC, TBX3 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). We detected peptides from these proteins preferentially in cells expressing wild-type CREB5 as compared to L434P or CREB3. We note that we also found peptides from LBD1 and DNMT1, but further evaluation showed that these proteins did not exhibit as strong a difference in AR-expressing prostate cancer cells, and we therefore concentrated on NFIC and TBX3, which also interacted with FOXA1 in our other RIME experiments (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> Table 3). These observations identified candidate CREB5 interactors, specifically NFIC and TBX3, that may be essential in ART resistance.</p></sec><sec id="s2-5"><title>TBX3 and NFIC are critical for AR-positive prostate cancer cells and ART resistance</title><p>To examine the relative contribution of TBX3 and NFIC to cell viability, we analyzed genome-scale RNAi screens performed in eight prostate cancer cell lines as a part of Project Achilles 2.20.1 (<xref ref-type="bibr" rid="bib16">Cowley et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Shalem et al., 2014</xref>; <xref ref-type="bibr" rid="bib67">Tsherniak et al., 2017</xref>). We found that in AR-positive cell lines (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, left) TBX3 and NFIC exhibited a pattern of cell line dependencies as observed for FOXA1. When examining AR-negative cell lines (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, right), we found that TBX3 exhibited no clear dependency, while NFIC exhibited modest dependency as compared to FOXA1. This close correlation of TBX3 and NFIC dependency with that observed for FOXA1 supports the conclusion that TBX3 and NFIC regulate prostate cancer cell viability in the AR setting. Furthermore, upon computing the average dependency scores in DEMETER, we found that NFIC and TBX3 ranked among the strongest dependencies in these prostate cancer cell lines while exhibiting limited overall dependency in the other 495 cell lines (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). The relative dependencies of NFIC and TBX3 were comparable to the strongest gene dependencies, such as FOXA1 and HOXB13, found in previous studies (<xref ref-type="bibr" rid="bib56">Pomerantz et al., 2015</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>TBX3 and NFIC are key regulators in prostate cancer cells including those that are enzalutamide resistant.</title><p>(<bold>A</bold>) Analysis of genome-scale RNAi screening data ranking the average dependency of 16,869 genes (x-axis) in androgen receptor (AR)-positive (Lleft) and AR-negative (Rrightt.) prostate cancer cell lines (Project Achilles 2.20.1). Average DEMETER score (y-axis) indicates the dependency correlations of FOXA1 and CREB5-interacting proteins. A negative DEMTER score indicates gene dependency in these specific PC cell lines. (<bold>B</bold>) Average ranks and percentiles based on DEMETER dependency scores are shown for selected genes in AR-positive, AR-negative, and non-PC cell lines. (<bold>C</bold>). shRNA was utilized to deplete experimental (NFIC, TBX3), negative (GFP) or positive controls (FOXA1) genes in LNCaP cells overexpressing CREB5. The overall cell numbers are depicted post -perturbation. A representative immunoblots depicts depletion of proteins from the proliferation experiments. Tubulin was used as a loading control. The relative depletion is quantified based on the average of all experiments after normalizing to tubulin. (<bold>D</bold>) CRISPR-Cas9 was utilized to deplete experimental (NFIC, TBX3), negative (GFP) or positive controls (FOXA1) genes in LNCaP cells that spontaneously developed resistance to enzalutamide. The overall cell numbers are depicted post -perturbation. A representative immunoblots depicts depletion of proteins from (C, upper panel) in proliferation experiments. Tubulin was used as a loading control. The relative depletion is quantified based on the average of all experiments after normalizing to tubulin. (<bold>E</bold>) ChIP-seq data from NFIC and TBX3 was analyzed to predict interaction with CREB5 or FOXA1 motifs. Enriched motifs, the targeted cell lines, and significance levels are depicted.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Immunoblots were used to detect expression of TBX3 and FOXA1 in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>The area highlighted was used to develop the figure for TBX3 and FOXA1 in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title>Immunoblots were used to detect expression of tubulin in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4—source data 4.</label><caption><title>The area highlighted was used to develop the figure for tubulin in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data4-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4—source data 5.</label><caption><title>Immunoblots were used to detect expression of NFIC in the indicated sample for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig4-data5-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4—source data 6.</label><caption><title>The area highlighted was used to develop the figure for NFIC in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig4-data6-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig4sdata7"><label>Figure 4—source data 7.</label><caption><title>Immunoblots were used to detect expression of V5-tagged CREB5 or luciferase in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig4-data7-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig4sdata8"><label>Figure 4—source data 8.</label><caption><title>The area highlighted was used to develop the figure for V5-tagged CREB5 or luciferase in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig4-data8-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig4sdata9"><label>Figure 4—source data 9.</label><caption><title>Immunoblots were used to detect expression of FOXA1 and TBX3 in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data9-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata10"><label>Figure 4—source data 10.</label><caption><title>The area highlighted was used to develop the figure for FOXA1 and TBX3 in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data10-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata11"><label>Figure 4—source data 11.</label><caption><title>Immunoblots were used to detect expression of tubulin in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data11-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata12"><label>Figure 4—source data 12.</label><caption><title>The area highlighted was used to develop the figure for tubulin in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data12-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata13"><label>Figure 4—source data 13.</label><caption><title>Immunoblots were used to detect expression of NFIC in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data13-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata14"><label>Figure 4—source data 14.</label><caption><title>The area highlighted was used to develop the figure for NFIC in the indicated samples for <xref ref-type="fig" rid="fig4">Figure 4D</xref>.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-73223-fig4-data14-v2.zip"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig4-v2.tif"/></fig><p>To further examine if TBX3 and NFIC were critical in models that exhibit ART resistance, we first performed RNAi-mediated gene depletion experiments in CREB5-overexpressing LNCaP cells in cultures exposed to enzalutamide (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). We found that suppression of TBX3 or NFIC using two shRNAs, as compared to a negative control (GFP), reduced the viability of CREB5-overexpressing LNCaP cells to the same extent as two positive control shRNAs that targeted FOXA1. This observation indicates that TBX3 and NFIC, like FOXA1, are required for optimal viability of CREB5 cells in the presence of enzalutamide. We also performed CRISPR-Cas9-mediated gene depletion experiments in a cell line model that spontaneously acquired enzalutamide resistance (<xref ref-type="bibr" rid="bib37">Kregel et al., 2016</xref>). In this cell line, we expressed three distinct sgRNAs that depleted FOXA1 or two sgRNAs that ablated TBX3 or NFIC, and we found that the sgRNAs against FOXA1, TBX3, or NFIC all reduced protein levels and decreased viability (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). We next examined if TBX3 or NFIC interacted with the key CREB5 co-factor FOXA1 in ChIP-seq experiments performed as part of the Encode project (<xref ref-type="bibr" rid="bib15">Consortium, 2012</xref>). Based on motif enrichment analyses of the TBX3 or NFIC binding sites, we observed statistically significant enrichment of FOXA1 binding motifs identified in experiments on breast or prostate cancer cell lines (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Like CREB5, NFIC also bound B-Zip motifs.</p><p>Given their role in regulating FOXA1 functions, we further examined the landscape of TBX3 and NFIC dysregulation in prostate cancer studies using whole-exome sequencing and whole transcriptome sequencing data from cBioPortal (<xref ref-type="bibr" rid="bib12">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib21">Gao et al., 2013</xref>) based on the 209 mCRPC samples collected by Stand Up 2 Cancer/Prostate Cancer Foundation (SU2C/PCF) (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>). We found that TBX3 and NFIC genomic amplifications together represented up to 13.3% of prostate cancers, in which notably higher amplification rates were observed in mCRPC studies as opposed to those sampling primary prostate cancer (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Upon examining expression and amplification data mCRPC samples (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>), we found that TBX3, NFIC, and FOXA1 were amplified or overexpressed in 7, 3, and 7% of mCRPC samples, respectively (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Of the 209 samples with expression data, we found a robust positive correlation between FOXA1 with TBX3 (Spearman’s correlation: 0.416; q-value: 1.48e-7) or NFIC (Spearman’s correlation: 0.536; q-value: 4.34e-15) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Together, we found TBX3 and NFIC were nuclear proteins associated with CREB5, FOXA1, and functionally impacted prostate cancer cell viability and ART resistance even absent of CREB5. In addition, they interacted specifically at FOXA1 motifs in cell lines, are amplified or overexpressed in prostate cancer patients, and their expression is associated with that of FOXA1 in mCRPC.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>TBX3</italic> and <italic>NFIC</italic> are amplified in prostate cancer cells.</title><p>(<bold>A</bold>) The genomic amplification rates of TBX3 and NFIC are examined in various prostate cancer studies. (<bold>B</bold>) In one metastatic castration-resistant prostate cancer (mCRPC) study, the rates of TBX3, NFIC, and FOXA1 gains are depicted. (<bold>C and D</bold>). The expression of TBX and NFIC are compared in one mCRPC study in which the regression line, Spearman’s correlation coefficients, and q-values are depicted.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig5-v2.tif"/></fig></sec><sec id="s2-6"><title>CREB5 regulates ART-resistant pathways in cell lines and mCRPC patients</title><p>To determine signaling functions of CREB5, we determined transcriptome expression patterns that were statistically associated with CREB5 expression in both cell lines and in mCRPC patients (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). Of the proteins that commonly interacted with CREB5, we utilized Enrichr (<xref ref-type="bibr" rid="bib13">Chen et al., 2013</xref>; <xref ref-type="bibr" rid="bib39">Kuleshov et al., 2016</xref>) to perform pathway enrichment analysis on the 335 proteins that bound both CREB5 and FOXA1 in our RIME profiling analysis. Based on the top 10 statistically significant signatures, we found that these 335 interactions associated with AR, cell cycle, as well as Notch, Wnt, and SMAD/TGFβ pathways (<xref ref-type="fig" rid="fig6">Figure 6B</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Integrative analysis of CREB5 activity.</title><p>(<bold>A</bold>) A workflow of the informatics analysis of CREB5 using in vitro and metastatic castration-resistant prostate cancer (mCRPC) data. (<bold>B</bold>) Spectrum of shared CREB5 and FOXA1 protein interactions identified by rapid immunoprecipitation and mass spectroscopy of endogenous proteins (RIME) are analyzed. The enriched pathways and statistical significance are presented for specific pathways. (<bold>C</bold>) Gene Set Enrichment Analysis (GSEA) analysis of RNA-seq data from CREB5 or luciferase overexpressing androgen receptor (AR)-positive (LNCaP and LAPC-4) and AR-negative (PC3, DU145) prostate cancer cells. (<bold>D</bold>) Based on RNA-seq from clinical mCRPC, Spearman’s correlation coefficients compare CREB5 expression with EMT, betaβ-catenin, and G2/M signaling. Correlation coefficient values (Rho, σ, x-axis) for CREB5 against each gene, as represented by a single dot, and the statistical significance (negative log of p-value, y-axis) areis displayed. Pp-vValue is marked (red dotted line).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig6-v2.tif"/></fig><p>To evaluate these findings, we collected mRNA from luciferase or CREB5-overexpressing prostate cancer cells, including the AR-dependent LNCaP and LAPC-4 cells, as well as the AR-negative PC3 and DU145 cells. We then used GSEA to identify pathways associated with CREB5 these cell lines (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). We found that CREB5 overexpression was significantly associated with enrichment of signaling pathways EMT and β-catenin, the Wnt transcription effector in the AR-positive LNCaP and LAPC4 cells, but not in the AR-negative cell lines PC3 and DU145. In clinical mCRPC samples, we analyzed RNA-sequencing datasets from the SU2C/PCF mCRPC cohort (n = 209) (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>). We computed the Spearman’s correlation coefficient for <italic>CREB5</italic> expression against each transcriptional target gene in the EMT, β-catenin, and cell cycle signatures. In mCRPC, we found that CREB5 expression was correlated with the expression of similar signaling programs we found in vitro, including EMT (<xref ref-type="bibr" rid="bib3">Alumkal et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">He et al., 2021</xref>) and β-catenin (<xref ref-type="bibr" rid="bib34">Isaacsson Velho et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Lee et al., 2015</xref>; <xref ref-type="bibr" rid="bib49">Murillo-Garzón and Kypta, 2017</xref>; <xref ref-type="fig" rid="fig6">Figure 6D</xref>). Together, the CREB5-associated nuclear protein interactions in cells and transcripts in mCRPC provide insights into the specific ART-resistant pathways that are activated by this transcription factor, showing the role CREB5 plays in regulating EMT and β-catenin signaling genes.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>We and others have demonstrated that transcription regulators, such as FOXA1, promote prostate cancer progression and resistance to ART and ADT. Our work identified other molecular events associated with transition towards resistance to second-generation ART and ADT. We did so by identifying reprogramming events associated with overexpressed CREB5, which exhibited shifts in binding at transcription regulatory elements as well as interaction with co-factors when cells were challenged with enzalutamide. In promoting proliferation in ART, CREB5 exhibited a strong degree of interaction with known AR transcription machinery, including FOXA1, HOXB13, and GRHL2, as well as novel prostate cancer regulators TBX3 and NFIC. The robust convergence of CREB5-FOXA1 function was observed through binding of transcription regulatory elements and interactions among nuclear proteins. The factors TBX3 and NFIC interacted with CREB5 but required an intact B/L-Zip domain. TBX3 and NFIC, two nuclear factors that are amplified or overexpressed in mCRPC, were vulnerabilities in other prostate cancer models, including ones that were ART resistant, and bound to FOXA1 transcription regulatory elements. Informatics modeling of the CREB5 activity through protein interactions and mCRPC transcription patterns indicated that CREB5 is associated with pathways found in patients resistant to enzalutamide (<xref ref-type="bibr" rid="bib3">Alumkal et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">He et al., 2021</xref>). Altogether, our study indicates that the dynamic binding properties of CREB5 mediate assembly of essential factors to AR and FOXA1 to promote resistant transcripts (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>A molecular model of the CREB5 complex and transcription promoting androgen receptor-targeted therapy (ART) resistance.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-fig7-v2.tif"/></fig><p>FOXA1 functions as an oncogenic pioneering and transcription factor in cancers, including prostate and breast (<xref ref-type="bibr" rid="bib22">Gerhardt et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Nakshatri and Badve, 2009</xref>; <xref ref-type="bibr" rid="bib61">Shah and Brown, 2019</xref>). FOXA1 is a critical dependency in prostate cancer cell line models (<xref ref-type="bibr" rid="bib56">Pomerantz et al., 2015</xref>), including those that transdifferentiate into AR-agnostic, neuroendocrine-like features (<xref ref-type="bibr" rid="bib6">Baca et al., 2021</xref>). Prior studies have broadly examined the binding patterns of FOXA1 with transcription regulatory elements in normal prostate tissue, primary prostate cancer, mCRPC, and neuroendocrine prostate cancers (<xref ref-type="bibr" rid="bib6">Baca et al., 2021</xref>; <xref ref-type="bibr" rid="bib56">Pomerantz et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Pomerantz et al., 2020</xref>), demonstrating transcriptional programs associated with prostate in development, tumor progression, and drug resistance. Although EMT is associated with neuroendocrine prostate cancers (<xref ref-type="bibr" rid="bib7">Beltran et al., 2016</xref>), AR-expressing mCRPCs that become enzalutamide resistance also show expression of EMT markers (<xref ref-type="bibr" rid="bib3">Alumkal et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">He et al., 2021</xref>). Together, the work presented herein demonstrates that the interactions of CREB5 and FOXA1 act as one mechanism that promotes EMT signaling in AR-positive-resistant cells.</p><p>We also found that TBX3 and NFIC interacted and correlated with FOXA1 in the setting of ART resistance based on RIME experiments and gene expression profile analyses of mCRPC samples. Independent of CREB5 and FOXA1, TBX3 expression has been shown to be required for viability of breast cancer cells (<xref ref-type="bibr" rid="bib4">Amir et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Krstic et al., 2016</xref>). In addition, NFI factors, NFIA/B/C/X, have previously been shown to interact with FOXA1 to promote the transcription of AR target genes (<xref ref-type="bibr" rid="bib24">Grabowska et al., 2014</xref>). Future studies that examine FOXA1 interactions in parallel through ChIP-seq and RIME are necessary to elucidate context-specific functions. In particular, it would be useful to characterize the universal subset of FOXA1 interactions in prostate cancer tumorigenesis as well as molecular changes associated with mutated forms of FOXA1 (<xref ref-type="bibr" rid="bib2">Adams et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Parolia et al., 2019</xref>).</p><p>Studies have identified increases in CREB5 as a marker for metastasis in ovarian, breast, and colorectal cancers (<xref ref-type="bibr" rid="bib9">Bhardwaj et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">He et al., 2017</xref>; <xref ref-type="bibr" rid="bib48">Molnár et al., 2018</xref>; <xref ref-type="bibr" rid="bib58">Qi and Ding, 2014</xref>). Functionally, Bardwaj et al. have identified CREB5 transcripts as a repressed target of miRNA-29c, a tumor-suppressive miRNA lost in the triple-negative subtype of breast cancer (<xref ref-type="bibr" rid="bib9">Bhardwaj et al., 2017</xref>). Forced overexpression of CREB5 promoted cell cycle and colony formation in this study. Altogether, these studies implicate pro-tumor CREB5 functions in cancers. While other CREB family members (<xref ref-type="bibr" rid="bib69">Welti et al., 2021</xref>) have been associated with therapy resistance in advanced prostate cancer, the differential RIME interaction profiles displayed by these two family member proteins, CREB5 and CREB3, exhibited dichotomous behavior with respect to binding of nuclear proteins in cancer cells. This suggests that the oncogenic roles of CREB5 and other CREB family members may be distinct and mediated through their structurally different N-terminal domains. As another key observation, we also find that experimental conditions, including cell culture and drug treatment, dramatically influenced CREB5 molecular interactions.</p><p>Our findings also support that transcription regulators may act as effective therapeutic targets in mCRPC. As examples, TBX3 and NFCI have been previously detected in large-scale proteomic approaches that interrogated prostate cancer tissue (<xref ref-type="bibr" rid="bib65">Sinha et al., 2019</xref>). This study demonstrates that they have key regulatory roles in prostate cancer cell viability and ART resistance. Antagonizing nuclear or transcription factors has been efficacious in recent examples, as inhibitors against EP300, an AR interacting protein, were efficacious in prostate cancer models (<xref ref-type="bibr" rid="bib35">Jin et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Lasko et al., 2017</xref>; <xref ref-type="bibr" rid="bib69">Welti et al., 2021</xref>). In regulating a pro-tumorigenic role in mCRPC, CREB5 require additional factors (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>, Tables 2–4), including JUN/ATF and SWI/SNF complex. While we have previously discussed that CREB5 functions differ from other CREB or ATF family members (<xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>), the context of how CREB5 interacts with CREB or ATF factors, such as potential hetero-dimerization at open regions of chromatin, still requires further resolution through biochemical approaches. Of bound SWI/SNF family members, we have previously discussed SMARCB1 as recurrent mutation in mCRPC (<xref ref-type="bibr" rid="bib5">Armenia et al., 2018</xref>), and its loss as a biomarker in malignant pediatric tumors (<xref ref-type="bibr" rid="bib31">Hong et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Howard et al., 2019</xref>). How CREB5 interacts with other chromatin remodeling complexes in ART resistance is an additional research direction that could improve our understanding of transcription processes that could act as targets in therapy-resistant mCRPC.</p><p>In summary, our observations implicate CREB5 as a driver of mCRPC. At the molecular level, our findings depict a complex model of therapy resistance that occurs in the nucleus of tumor cells that permits the activation of oncogenic signaling pathways. Furthering the understanding of these underlying changes may inform of additional research avenues and precision strategies for advanced cancer patients that depend on CREB5.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Genome-scale ORF screen analysis</title><p>We analyzed a published genome-scale ORF screen performed in LNCaP cells (<xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>). Specifically, we compared the experimental arms conducted in control media (FCS) with androgens and androgen stripped media (CSS) containing enzalutamide. Z-scores represent the relative effects of each ORF on cell proliferation after 25 days in culture.</p></sec><sec id="s4-2"><title>Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME)</title><p>Upon preparation of cells in each experimental arm, two replicates of 50 million cells each were fixed in 1% formaldehyde for 10 min. Reactions were terminated in 0.125 M glycine for 5 min. Cells were subsequently collected and lysed at 4°C in RIPA buffer (Cell Signaling Technology, 13202S) containing protease inhibitor cocktail (Roche, 11836145001). Cells were then sonicated with a Covaris sonicator to yield DNA fragments averaging around 3000 nucleotides. To target V5-tagged CREB5, CREB5 L434P, or CREB5, 20 μL of V5 antibody (Cell Signaling Technology, 58613) was added to the supernatant. To target FOXA1, each sample was incubated with 20 μL of two FOXA1 antibodies against distinct epitopes (Abcam, ab23738, and Cell Signaling Technology, 58613). Samples were incubated with gentle mixing at 4°C overnight. The following morning, RIPA buffer was used to wash Protein A magnetic beads (Life Technologies, 88846) five times, and the beads were then resuspended into the original volume. 50 μL of the bead mixture was added to each sample and incubated for 2 hr at 4°C. Each sample was then washed five times with 300 μL of RIPA buffer, followed by five times with 300 μL of ammonium bicarbonate (50 μM), and finally resuspended in 50 μL of ammonium bicarbonate (50 μM). These samples on the beads were then sent for proteomic analysis at the Taplin Mass Spectrometry Facility at Harvard Medical School. Upon obtaining mapped reads, only unique peptides of proteins were considered for subsequent analysis. Beads were subjected to trypsin digestion procedure (<xref ref-type="bibr" rid="bib64">Shevchenko et al., 1996</xref>), then washed and dehydrated with acetonitrile for 10 min followed by removal of acetonitrile. The beads were then completely dried in a speed-vac. Rehydration of the beads was with 50 mM ammonium bicarbonate solution containing 12.5 ng/µL modified sequencing-grade trypsin (Promega, Madison, WI) at 4°C. After 45 min, the excess trypsin solution was removed and replaced with 50 mM ammonium bicarbonate solution to just cover the gel pieces. Samples were then placed in a 37°C room overnight. Peptides were later extracted by removing the ammonium bicarbonate solution, followed by one wash with a solution containing 50% acetonitrile and 1% formic acid. The extracts were then dried in a speed-vac (~1 hr). The samples were then stored at 4°C until analysis. On the day of analysis, the samples were reconstituted in 5–10 µL of HPLC solvent A (2.5% acetonitrile, 0.1% formic acid). A nano-scale reverse-phase HPLC capillary column was created by packing 2.6 µm C18 spherical silica beads into a fused silica capillary (100µm inner diameter × ~30cm length) with a flame-drawn tip (<xref ref-type="bibr" rid="bib55">Peng and Gygi, 2001</xref>). After equilibrating the column, each sample was loaded via a Famos auto sampler (LC Packings, San Francisco, CA) onto the column. A gradient was formed and peptides were eluted with increasing concentrations of solvent B (97.5% acetonitrile, 0.1% formic acid). As peptides eluted, they were subjected to electrospray ionization and then entered into an LTQ Orbitrap Velos Pro ion-trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Peptides were detected, isolated, and fragmented to produce a tandem mass spectrum of specific fragment ions for each peptide. Peptide sequences (and hence protein identity) were determined by matching protein databases with the acquired fragmentation pattern by the software program, Sequest (Thermo Fisher Scientific) (<xref ref-type="bibr" rid="bib19">Eng et al., 1994</xref>). All databases include a reversed version of all the sequences, and the data was filtered to between a 1 and 2% peptide false discovery rate.</p></sec><sec id="s4-3"><title>Population doubling</title><p>100~200k cells were plated in 12-well plates in either control media (FCS) or low androgen media (CSS) with 10 μM of enzalutamide. Cell counts and relative cell viability were determined after 7 days using a Vi-Cell. Original cell counts were subtracted before doubling was computed.</p></sec><sec id="s4-4"><title>Generation of CREB5 point mutants</title><p>A pDNR221 CREB5 plasmid was used as a backbone for point mutagenesis. Per the five point mutants, forward and reverse primers were designed to mutagenize nucleotides of CREB5 to reflect the corresponding changes in protein sequence. Primers were designed with primerX (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.org/primerx">http://www.bioinformatics.org/primerx</ext-link>). Detailed reaction conditions were followed according to a QuikChange II Site-Directed Mutagenesis Kit (Agilent, 2005230). The mutant clones were each sequenced to confirm their identities before subsequent use in recombination reactions. LR Clonase II (Invitrogen, 11791-020) was used to catalyze the recombination reactions to insert each mutated CREB5 ORF into a puromycin-resistant lentiviral pLX307 vector. Positive clones were then sequenced to confirm the identity of the resulting mutant vectors used for further experimentation.</p></sec><sec id="s4-5"><title>CRISPR-Cas9 experiments</title><p>To generates sgRNAs, oligos were cloned into a pXPR_003 vector as previously cited (<xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>). Blasticidin-resistant Cas9-positive LNCaP enzalutamide-resistant cells were cultured in 10 μg/mL blasticidin (Thermo Fisher Scientific, NC9016621) for 72 hr to select for cells with optimal Cas9 activity. One million cells were seeded in parallel in 6-well plates and infected with lentiviruses expressing puromycin-resistant sgRNAs targeting FOXA1, TBX3, NFIC, or GFP control. After 48 hr, cells were counted and seeded, using a Vi-Cell, in FCS media with 20 μM enzalutamide at a density of 20,000 cells per well in 6-well plate for a proliferation assay. After 24 hr, cells were subjected to puromycin selection for 3 days. 7 days later, cells were counted again with a Vi-Cell to assess viability, representing a total of 12 days. The target sequences against GFP were <named-content content-type="sequence">AGCTGGACGGCGACGTAAA</named-content> (sgGFP1) and <named-content content-type="sequence">GCCACAAGTTCAGC GTGTCG</named-content> (sgGFP2). The target sequences against FOXA1 were <named-content content-type="sequence">GTTGGACGGC GCGTACGCCA</named-content> (sgFOXA1-1), <named-content content-type="sequence">GTAGTAGCTGTTCCAGTCGC</named-content> (sgFOXA1-2), and <named-content content-type="sequence">ACTGCGCCCCCCATA AGCTC</named-content> (sgFOXA1-4). The target sequences against TBX3 were <named-content content-type="sequence">GAAAAGGTGAGCCTTGACCG</named-content> (sgTBX3-1) and <named-content content-type="sequence">GCTCTTACAATGTGGAACCG</named-content> (sgTBX3-2). The target sequences against NFIC were <named-content content-type="sequence">ACGGCCACGCCAATGTGGTG </named-content>(sgNFIC-1) and <named-content content-type="sequence">GCTGAGCATCACCGGCAAGA</named-content> (sgNFIC-2).</p></sec><sec id="s4-6"><title>shRNA experiments</title><p>Lentiviruses expressing shRNAs for AR, FOXA1, TBX3, NFIC, or GFP were used to infect LNCaP cells grown in FCS media. Between 48 and 72 hr post infection, protein lysates were collected to determine the extent of suppression. After confirming suppression, respective cells were counted and directly seeded for proliferation experiments. All shRNA constructs were acquired from the Broad Institute Genetic Perturbation Platform (<ext-link ext-link-type="uri" xlink:href="https://portals.broadinstitute.org/gpp/public/">https://portals.broadinstitute.org/gpp/public/</ext-link>). The target sequence against GFP was <named-content content-type="sequence">ACAACAGCCACAACGTCTATA</named-content> (sgGFP). The target sequences against AR were <named-content content-type="sequence">GAGCGTGGACTTTCCGGAAAT</named-content> (shAR1), <named-content content-type="sequence">GATGTCTTCTGCCTGTTATAA</named-content> (shAR2), and <named-content content-type="sequence">CGCGACTACTACAACTTTCCA</named-content> (shAR3). The target sequences against FOXA1 were <named-content content-type="sequence">TCTAGTTTGTGGAGGGTTATT</named-content> (shFOXA1-1) and <named-content content-type="sequence">GCGTACTACCAAGGTGTGTAT</named-content> (shFOXA1-2). The target sequences against TBX3 were <named-content content-type="sequence">GCATACCAGAATGATAAGAT</named-content><named-content content-type="sequence">A</named-content> (shTBX3-2) and <named-content content-type="sequence">GCTGCTGATGACTGTCGTTAT</named-content> (shTBX3-3). The target sequences against NFIC were <named-content content-type="sequence">GATGGACAAGTCACCATTCAA</named-content> (shNFIC-2) and <named-content content-type="sequence">CCCGGTGAAGAAGACAGAGAT</named-content> (shNFIC-4).</p></sec><sec id="s4-7"><title>RNA-seq experiments</title><p>For RNA-seq experiments, AR-positive (LNCaP, LAPC-4) cells and AR-negative (PC3, DU145) cells expressing either luciferase or CREB5 were cultured in FCS media. For RNA-seq experiments, library preparations, quality control, and sequencing on a HiSeq2500 (Illumina) were performed and analyzed by the Dana-Farber Molecular Biology core facility based on prior studies (<xref ref-type="bibr" rid="bib33">Hwang et al., 2019</xref>).</p></sec><sec id="s4-8"><title>Immunoblotting</title><p>Cells were lysed using 2× sample buffer (62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, Coomassie dye) and freshly added 4% β-mercaptoethanol. Lysed cells were scraped, transferred into a 1.5 mL microcentrifuge tube, sonicated for 15 s, and boiled at 95°C for 10 min. Proteins were resolved in NuPAGE 4–12% Bis-Tris Protein gels (Thermo Fisher Scientific) and run with NuPAGE MOPS SDS Running Buffer (Thermo Fisher Scientific, NP0001). Proteins were transferred to nitrocellulose membranes using an iBlot apparatus (Thermo Fisher Scientific). Membranes were blocked in Odyssey Blocking Buffer (LI-COR Biosciences, 927-70010) for 1 hr at room temperature, and membranes were then cut and incubated in primary antibodies diluted in Odyssey Blocking Buffer at 4°C overnight. The following morning, membranes were washed with phosphate-buffered saline, 0.1% Tween (PBST) and incubated with fluorescent anti-rabbit or anti-mouse secondary antibodies at a dilution of 1:5000 (Thermo Fisher Scientific, NC9401842 [rabbit] and NC0046410 [mouse]) for 1 hr at room temperature. Membranes were again washed with PBST and then imaged using an Odyssey Imaging System (LI-COR Biosciences). Primary antibodies used include V5 (Cell Signaling Technology, 13202S), β-actin (Cell Signaling Technology, 8457L), FOXA1 (Cell Signaling, 58613), TBX3 (Life Technologies, 424800), NFIC (Abcam, ab245597), and tubulin (Cell Signaling, 3873S).</p></sec><sec id="s4-9"><title>Overlap analysis of CREB5 binding sites</title><p>Bed files containing peak summit locations determined by MACS2 from CREB5 ChIP-seq data were intersected with the indicated datasets using BEDtools v2.27.1 (<xref ref-type="bibr" rid="bib59">Quinlan and Hall, 2010</xref>). To assess overlap with FOXA1 binding sites, FOXA1 ChIP-seq datasets from 23 prostate adenocarcinoma patient-derived xenografts (<xref ref-type="bibr" rid="bib51">Nguyen et al., 2017</xref>) and tissue (<xref ref-type="bibr" rid="bib56">Pomerantz et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Pomerantz et al., 2020</xref>) were merged to create a FOXA1 union peak set. To assess overlap of CREB5 binding and various sets of AR binding sites, we first created a union set of CREB5 peaks that were present with or without enzalutamide treatment. This CREB5 peak set was intersected with the indicated AR peaks sets (<xref ref-type="fig" rid="fig2">Figure 2B</xref>) from <xref ref-type="bibr" rid="bib56">Pomerantz et al., 2015</xref> and <xref ref-type="bibr" rid="bib57">Pomerantz et al., 2020</xref>. The percentages of each class of AR+CREB5+peaks were assessed for overlap with the union set of FOXA1 peaks in <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</p></sec><sec id="s4-10"><title>Project Achilles 2.20.1 analysis</title><p>Of the total of 503 cell lines, we analyzed a published genome-scale RNAi screen of eight prostate cancer cell lines (<xref ref-type="bibr" rid="bib16">Cowley et al., 2014</xref>; <xref ref-type="bibr" rid="bib62">Shalem et al., 2014</xref>; <xref ref-type="bibr" rid="bib67">Tsherniak et al., 2017</xref>) whereby we averaged the dependency for each gene. Cell lines included NCIH660 (NEPC-like), PC3 and DU145 (AR negative), 22RV1 (expressing an AR V7 splice variant), LNCaP, VCaP, and MDAPCA2B (AR positive and dependent), and PRECLH (normal immortalized prostate epithelium).</p></sec><sec id="s4-11"><title>Motif enrichment analysis</title><p>Known motifs enriched in TBX3 and NFIC ChIP-seq data from HepG2 cells (GEO: GSM2825557, GSM2902642) compared to a whole-genome background were identified with Homer version 4.17 (<xref ref-type="bibr" rid="bib29">Heinz et al., 2010</xref>). Selected examples from the most significantly enriched known motifs are shown (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p></sec><sec id="s4-12"><title>Expression association analysis of CREB5 in mCRPC</title><p>We analyzed RNA-sequencing data from an updated combined cohort of men with mCRPC from multiple institutions comprising the SU2C/PCF Prostate Cancer Dream Team (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>). RNA-seq data, normalized in units of transcripts per million (TPM), was available from 208 patients. Expression data was previously examined and adjusted for batch effects using ComBat (<xref ref-type="bibr" rid="bib36">Johnson et al., 2007</xref>) via the R Bioconductor package ‘sva’ (<xref ref-type="bibr" rid="bib44">Leek et al., 2012</xref>), V3.22.0. The Spearman correlations were determined for CREB5 against all detectable transcripts in these samples. This profile of association was further examined with focus on CREB5 and its association with genes in the indicated pathways using predefined MSigDB signatures.</p></sec><sec id="s4-13"><title>Cell lines and authentication</title><p>The cell lines used in this study were directly ordered from American Type Culture Collection (ATCC) or identities have been confirmed through their STR profiling analyses. None of the cell lines we have used are frequently misidentified by standards of the International Cell Line Authentication Committee. Micoplasma contamination was routinely tested using MycoAlert (LT07-118, Lonza).</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>is a consultant for Astrin Biosciences, Principal Investigator for Caris Life Sciences Genitourinary disease working group</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf4"><p>serves as Advisory/Consulting for Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, Monte Rosa, received research support from Novartis, BMS, has equity with Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, receives travel reimbursement from Roche/Genentech, and holds patents including Institutional patents filed on chromatin mutations and immunotherapy response, and methods for clinical interpretation</p></fn><fn fn-type="COI-statement" id="conf5"><p>Reviewing editor, eLife</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Methodology, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation, Methodology, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology, Resources, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Methodology, Resources, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Methodology, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Investigation, Methodology, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Methodology, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Conceptualization, Investigation, Resources, Supervision, Validation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Conceptualization, Investigation, Methodology, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Formal analysis, Methodology, Resources, Supervision, Validation, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-73223-transrepform1-v2.pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Tables.</title><p>Table 1. Z-scores for each gene from the genome-scale screen are presented and ranked.Table 2. Unique peptide counts are displayed for the RIME experiment based on each condition.Table 3. Unique peptide counts are displayed for the RIME experiment based on each condition.Table 4. Unique peptide counts are displayed for the RIME experiment based on each condition.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-73223-supp1-v2.xlsx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>RIME data has been shared through supplementary tables in Supplementary File 1.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Ji-Heui</surname><given-names>S</given-names></name><name><surname>Xintao</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>CREB5 promotes resistance to androgen-receptor antagonists and androgen deprivation in prostate cancer</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137775">GSE137775</pub-id></element-citation></p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>ENCODE</collab></person-group><year iso-8601-date="2017">2017</year><data-title>ChIP-seq from HepG2 (ENCLB611SYU)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2825557">GSM2825557</pub-id></element-citation></p><p><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>ChIP-seq for NFIC</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2902642">GSM2902642</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported in part by the Weizmann Institute of Science – National Postdoctoral Award Program for Advancing Women in Science (to RA), Targets of Cancer Training program grant T32 CA009138 (to ML), Ray of Light Foundation (to HEB), NIH/NCI (K00 CA212221) (to JPR), American Cancer Society-AstraZeneca (PF-16-142-01-TBE) (to JH), Young Investigator Award from the American Society of Clinical Oncologists (ASCO) and by the PhRMA Foundation and Kure It Cancer Research Foundation (to SCB), U01 CA233100 (EMV), Mark Foundation Emerging Leader Award (EMV), U.S. National Institutes of Health/National Cancer Institute: U01 CA176058 (to WCH). We acknowledge Joshua Pan from Dana Farber Institute and Broad Institute of MIT and Harvard for designing approaches for co-dependency analysis.</p><p>Graphical figures were created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">https://biorender.com/</ext-link>.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Cyrta</surname><given-names>J</given-names></name><name><surname>Heller</surname><given-names>G</given-names></name><name><surname>Prandi</surname><given-names>D</given-names></name><name><surname>Armenia</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>I</given-names></name><name><surname>Cieslik</surname><given-names>M</given-names></name><name><surname>Benelli</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Fedrizzi</surname><given-names>T</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Robinson</surname><given-names>BD</given-names></name><name><surname>De Sarkar</surname><given-names>N</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Tomlins</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Nava Rodrigues</surname><given-names>D</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Pritchard</surname><given-names>CC</given-names></name><name><surname>Mateo</surname><given-names>J</given-names></name><name><surname>Bianchini</surname><given-names>D</given-names></name><name><surname>Miranda</surname><given-names>S</given-names></name><name><surname>Carreira</surname><given-names>S</given-names></name><name><surname>Rescigno</surname><given-names>P</given-names></name><name><surname>Filipenko</surname><given-names>J</given-names></name><name><surname>Vinson</surname><given-names>J</given-names></name><name><surname>Montgomery</surname><given-names>RB</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Heath</surname><given-names>EI</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Taplin</surname><given-names>ME</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>deBono</surname><given-names>JS</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genomic correlates of clinical outcome in advanced prostate cancer</article-title><source>PNAS</source><volume>116</volume><fpage>11428</fpage><lpage>11436</lpage><pub-id pub-id-type="doi">10.1073/pnas.1902651116</pub-id><pub-id pub-id-type="pmid">31061129</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>EJ</given-names></name><name><surname>Karthaus</surname><given-names>WR</given-names></name><name><surname>Hoover</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Gruet</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>DiLoreto</surname><given-names>R</given-names></name><name><surname>Chhangawala</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Watson</surname><given-names>PA</given-names></name><name><surname>Davicioni</surname><given-names>E</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Barbieri</surname><given-names>CE</given-names></name><name><surname>Bose</surname><given-names>R</given-names></name><name><surname>Leslie</surname><given-names>CS</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes</article-title><source>Nature</source><volume>571</volume><fpage>408</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1318-9</pub-id><pub-id pub-id-type="pmid">31243370</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alumkal</surname><given-names>JJ</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Lu</surname><given-names>E</given-names></name><name><surname>Beer</surname><given-names>TM</given-names></name><name><surname>Thomas</surname><given-names>GV</given-names></name><name><surname>Latour</surname><given-names>E</given-names></name><name><surname>Aggarwal</surname><given-names>R</given-names></name><name><surname>Cetnar</surname><given-names>J</given-names></name><name><surname>Ryan</surname><given-names>CJ</given-names></name><name><surname>Tabatabaei</surname><given-names>S</given-names></name><name><surname>Bailey</surname><given-names>S</given-names></name><name><surname>Turina</surname><given-names>CB</given-names></name><name><surname>Quigley</surname><given-names>DA</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><name><surname>Foye</surname><given-names>A</given-names></name><name><surname>Youngren</surname><given-names>JF</given-names></name><name><surname>Urrutia</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Weinstein</surname><given-names>AS</given-names></name><name><surname>Friedl</surname><given-names>V</given-names></name><name><surname>Rettig</surname><given-names>M</given-names></name><name><surname>Reiter</surname><given-names>RE</given-names></name><name><surname>Spratt</surname><given-names>DE</given-names></name><name><surname>Gleave</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>CP</given-names></name><name><surname>Stuart</surname><given-names>JM</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Small</surname><given-names>EJ</given-names></name><name><surname>Witte</surname><given-names>ON</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance</article-title><source>PNAS</source><volume>117</volume><fpage>12315</fpage><lpage>12323</lpage><pub-id pub-id-type="doi">10.1073/pnas.1922207117</pub-id><pub-id pub-id-type="pmid">32424106</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amir</surname><given-names>S</given-names></name><name><surname>Simion</surname><given-names>C</given-names></name><name><surname>Umeh-Garcia</surname><given-names>M</given-names></name><name><surname>Krig</surname><given-names>S</given-names></name><name><surname>Moss</surname><given-names>T</given-names></name><name><surname>Carraway</surname><given-names>KL</given-names></name><name><surname>Sweeney</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Regulation of the T-box transcription factor Tbx3 by the tumour suppressor microRNA-206 in breast cancer</article-title><source>British Journal of Cancer</source><volume>114</volume><fpage>1125</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.73</pub-id><pub-id pub-id-type="pmid">27100732</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armenia</surname><given-names>J</given-names></name><name><surname>Wankowicz</surname><given-names>SAM</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Kundra</surname><given-names>R</given-names></name><name><surname>Reznik</surname><given-names>E</given-names></name><name><surname>Chatila</surname><given-names>WK</given-names></name><name><surname>Chakravarty</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>GC</given-names></name><name><surname>Coleman</surname><given-names>I</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Pritchard</surname><given-names>C</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Barbieri</surname><given-names>CE</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Zafeiriou</surname><given-names>Z</given-names></name><name><surname>Miranda</surname><given-names>S</given-names></name><name><surname>Bielski</surname><given-names>CM</given-names></name><name><surname>Penson</surname><given-names>AV</given-names></name><name><surname>Tolonen</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>FW</given-names></name><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>YM</given-names></name><name><surname>Lonigro</surname><given-names>R</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Taplin</surname><given-names>M-E</given-names></name><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>de Bono</surname><given-names>JS</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><collab>PCF/SU2C International Prostate Cancer Dream Team</collab><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The long tail of oncogenic drivers in prostate cancer</article-title><source>Nature Genetics</source><volume>50</volume><fpage>645</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0078-z</pub-id><pub-id pub-id-type="pmid">29610475</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baca</surname><given-names>SC</given-names></name><name><surname>Takeda</surname><given-names>DY</given-names></name><name><surname>Seo</surname><given-names>J-H</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Ku</surname><given-names>SY</given-names></name><name><surname>Arafeh</surname><given-names>R</given-names></name><name><surname>Arnoff</surname><given-names>T</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>C</given-names></name><name><surname>O’Connor</surname><given-names>E</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Alaiwi</surname><given-names>SA</given-names></name><name><surname>Corona</surname><given-names>RI</given-names></name><name><surname>Fonseca</surname><given-names>MAS</given-names></name><name><surname>Giambartolomei</surname><given-names>C</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Lim</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Sheahan</surname><given-names>A</given-names></name><name><surname>Nassar</surname><given-names>A</given-names></name><name><surname>Berchuck</surname><given-names>JE</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>HM</given-names></name><name><surname>Coleman</surname><given-names>IM</given-names></name><name><surname>Kaipainen</surname><given-names>A</given-names></name><name><surname>De Sarkar</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Korthauer</surname><given-names>K</given-names></name><name><surname>Pomerantz</surname><given-names>MM</given-names></name><name><surname>Ellis</surname><given-names>L</given-names></name><name><surname>Pasaniuc</surname><given-names>B</given-names></name><name><surname>Lawrenson</surname><given-names>K</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name><name><surname>Zoubeidi</surname><given-names>A</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Long</surname><given-names>HW</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1979</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22139-7</pub-id><pub-id pub-id-type="pmid">33785741</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Prandi</surname><given-names>D</given-names></name><name><surname>Mosquera</surname><given-names>JM</given-names></name><name><surname>Benelli</surname><given-names>M</given-names></name><name><surname>Puca</surname><given-names>L</given-names></name><name><surname>Cyrta</surname><given-names>J</given-names></name><name><surname>Marotz</surname><given-names>C</given-names></name><name><surname>Giannopoulou</surname><given-names>E</given-names></name><name><surname>Chakravarthi</surname><given-names>BVSK</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name><name><surname>Tagawa</surname><given-names>ST</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer</article-title><source>Nature Medicine</source><volume>22</volume><fpage>298</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1038/nm.4045</pub-id><pub-id pub-id-type="pmid">26855148</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernard</surname><given-names>D</given-names></name><name><surname>Pourtier-Manzanedo</surname><given-names>A</given-names></name><name><surname>Gil</surname><given-names>J</given-names></name><name><surname>Beach</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Myc confers androgen-independent prostate cancer cell growth</article-title><source>The Journal of Clinical Investigation</source><volume>112</volume><fpage>1724</fpage><lpage>1731</lpage><pub-id pub-id-type="doi">10.1172/JCI19035</pub-id><pub-id pub-id-type="pmid">14660748</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhardwaj</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Rajapakshe</surname><given-names>K</given-names></name><name><surname>Tachibana</surname><given-names>K</given-names></name><name><surname>Ganesan</surname><given-names>N</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Gunaratne</surname><given-names>PH</given-names></name><name><surname>Coarfa</surname><given-names>C</given-names></name><name><surname>Bedrosian</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer</article-title><source>Oncotarget</source><volume>8</volume><fpage>19645</fpage><lpage>19660</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14902</pub-id><pub-id pub-id-type="pmid">28160548</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bluemn</surname><given-names>EG</given-names></name><name><surname>Coleman</surname><given-names>IM</given-names></name><name><surname>Lucas</surname><given-names>JM</given-names></name><name><surname>Coleman</surname><given-names>RT</given-names></name><name><surname>Hernandez-Lopez</surname><given-names>S</given-names></name><name><surname>Tharakan</surname><given-names>R</given-names></name><name><surname>Bianchi-Frias</surname><given-names>D</given-names></name><name><surname>Dumpit</surname><given-names>RF</given-names></name><name><surname>Kaipainen</surname><given-names>A</given-names></name><name><surname>Corella</surname><given-names>AN</given-names></name><name><surname>Yang</surname><given-names>YC</given-names></name><name><surname>Nyquist</surname><given-names>MD</given-names></name><name><surname>Mostaghel</surname><given-names>E</given-names></name><name><surname>Hsieh</surname><given-names>AC</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name><name><surname>Brown</surname><given-names>LG</given-names></name><name><surname>Nguyen</surname><given-names>HM</given-names></name><name><surname>Pienta</surname><given-names>K</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name><name><surname>Schweizer</surname><given-names>M</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Wise</surname><given-names>D</given-names></name><name><surname>Rennie</surname><given-names>PS</given-names></name><name><surname>Vessella</surname><given-names>RL</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling</article-title><source>Cancer Cell</source><volume>32</volume><fpage>474</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.09.003</pub-id><pub-id pub-id-type="pmid">29017058</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bubley</surname><given-names>GJ</given-names></name><name><surname>Balk</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide</article-title><source>Journal of Clinical Oncology</source><volume>35</volume><fpage>2103</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.72.8808</pub-id><pub-id pub-id-type="pmid">28414609</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>EY</given-names></name><name><surname>Tan</surname><given-names>CM</given-names></name><name><surname>Kou</surname><given-names>Y</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Meirelles</surname><given-names>GV</given-names></name><name><surname>Clark</surname><given-names>NR</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool</article-title><source>BMC Bioinformatics</source><volume>14</volume><elocation-id>128</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-14-128</pub-id><pub-id pub-id-type="pmid">23586463</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comstock</surname><given-names>CES</given-names></name><name><surname>Augello</surname><given-names>MA</given-names></name><name><surname>Goodwin</surname><given-names>JF</given-names></name><name><surname>de Leeuw</surname><given-names>R</given-names></name><name><surname>Schiewer</surname><given-names>MJ</given-names></name><name><surname>Ostrander</surname><given-names>WF</given-names><suffix>Jr</suffix></name><name><surname>Burkhart</surname><given-names>RA</given-names></name><name><surname>McClendon</surname><given-names>AK</given-names></name><name><surname>McCue</surname><given-names>PA</given-names></name><name><surname>Trabulsi</surname><given-names>EJ</given-names></name><name><surname>Lallas</surname><given-names>CD</given-names></name><name><surname>Gomella</surname><given-names>LG</given-names></name><name><surname>Centenera</surname><given-names>MM</given-names></name><name><surname>Brody</surname><given-names>JR</given-names></name><name><surname>Butler</surname><given-names>LM</given-names></name><name><surname>Tilley</surname><given-names>WD</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Targeting cell cycle and hormone receptor pathways in cancer</article-title><source>Oncogene</source><volume>32</volume><fpage>5481</fpage><lpage>5491</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.83</pub-id><pub-id pub-id-type="pmid">23708653</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consortium</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>An integrated encyclopedia of DNA elements in the human genome</article-title><source>Nature</source><volume>489</volume><fpage>57</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/nature11247</pub-id><pub-id pub-id-type="pmid">22955616</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Scott</surname><given-names>JA</given-names></name><name><surname>Rusin</surname><given-names>S</given-names></name><name><surname>East-Seletsky</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>LD</given-names></name><name><surname>Gerath</surname><given-names>WF</given-names></name><name><surname>Pantel</surname><given-names>SE</given-names></name><name><surname>Lizotte</surname><given-names>PH</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Dwinell</surname><given-names>E</given-names></name><name><surname>Aoyama</surname><given-names>S</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Harrington</surname><given-names>W</given-names></name><name><surname>Gelfand</surname><given-names>E</given-names></name><name><surname>Green</surname><given-names>TM</given-names></name><name><surname>Tomko</surname><given-names>MJ</given-names></name><name><surname>Gopal</surname><given-names>S</given-names></name><name><surname>Wong</surname><given-names>TC</given-names></name><name><surname>Wong</surname><given-names>TC</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Howell</surname><given-names>S</given-names></name><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Liefeld</surname><given-names>T</given-names></name><name><surname>Jang</surname><given-names>D</given-names></name><name><surname>Bistline</surname><given-names>J</given-names></name><name><surname>Hill Meyers</surname><given-names>B</given-names></name><name><surname>Armstrong</surname><given-names>SA</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name><name><surname>Stegmaier</surname><given-names>K</given-names></name><name><surname>Reich</surname><given-names>M</given-names></name><name><surname>Pellman</surname><given-names>D</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies</article-title><source>Scientific Data</source><volume>1</volume><elocation-id>140035</elocation-id><pub-id pub-id-type="doi">10.1038/sdata.2014.35</pub-id><pub-id pub-id-type="pmid">25984343</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dwarki</surname><given-names>VJ</given-names></name><name><surname>Montminy</surname><given-names>M</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Both the basic region and the “leucine zipper” domain of the cyclic AMP response element binding (CREB) protein are essential for transcriptional activation</article-title><source>The EMBO Journal</source><volume>9</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb08099.x</pub-id><pub-id pub-id-type="pmid">2136830</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elmarakeby</surname><given-names>HA</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>AlDubayan</surname><given-names>SH</given-names></name><name><surname>Salari</surname><given-names>K</given-names></name><name><surname>Richter</surname><given-names>C</given-names></name><name><surname>Arnoff</surname><given-names>TE</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Van Allen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Biologically informed deep neural 24 880 network for prostate cancer classification and discovery</article-title><source>Bioinformatics (Oxford, England)</source><volume>1</volume><elocation-id>e6446</elocation-id><pub-id pub-id-type="doi">10.1101/2020.12.08.416446</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eng</surname><given-names>JK</given-names></name><name><surname>McCormack</surname><given-names>AL</given-names></name><name><surname>Yates</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database</article-title><source>Journal of the American Society for Mass Spectrometry</source><volume>5</volume><fpage>976</fpage><lpage>989</lpage><pub-id pub-id-type="doi">10.1016/1044-0305(94)80016-2</pub-id><pub-id pub-id-type="pmid">24226387</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>SY</given-names></name><name><surname>Ronai</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Ubiquitination and degradation of ATF2 are dimerization dependent</article-title><source>Molecular and Cellular Biology</source><volume>19</volume><fpage>3289</fpage><lpage>3298</lpage><pub-id pub-id-type="doi">10.1128/MCB.19.5.3289</pub-id><pub-id pub-id-type="pmid">10207054</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Dresdner</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pl1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhardt</surname><given-names>J</given-names></name><name><surname>Montani</surname><given-names>M</given-names></name><name><surname>Wild</surname><given-names>P</given-names></name><name><surname>Beer</surname><given-names>M</given-names></name><name><surname>Huber</surname><given-names>F</given-names></name><name><surname>Hermanns</surname><given-names>T</given-names></name><name><surname>Müntener</surname><given-names>M</given-names></name><name><surname>Kristiansen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer</article-title><source>The American Journal of Pathology</source><volume>180</volume><fpage>848</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.10.021</pub-id><pub-id pub-id-type="pmid">22138582</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glont</surname><given-names>SE</given-names></name><name><surname>Papachristou</surname><given-names>EK</given-names></name><name><surname>Sawle</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>KA</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Siersbaek</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0215340</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0215340</pub-id><pub-id pub-id-type="pmid">30970003</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabowska</surname><given-names>MM</given-names></name><name><surname>Elliott</surname><given-names>AD</given-names></name><name><surname>DeGraff</surname><given-names>DJ</given-names></name><name><surname>Anderson</surname><given-names>PD</given-names></name><name><surname>Anumanthan</surname><given-names>G</given-names></name><name><surname>Yamashita</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Friedman</surname><given-names>DB</given-names></name><name><surname>Hachey</surname><given-names>DL</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Sheehan</surname><given-names>JH</given-names></name><name><surname>Ahn</surname><given-names>J-M</given-names></name><name><surname>Raj</surname><given-names>GV</given-names></name><name><surname>Piston</surname><given-names>DW</given-names></name><name><surname>Gronostajski</surname><given-names>RM</given-names></name><name><surname>Matusik</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>NFI transcription factors interact with FOXA1 to regulate prostate-specific gene expression</article-title><source>Molecular Endocrinology (Baltimore, Md.)</source><volume>28</volume><fpage>949</fpage><lpage>964</lpage><pub-id pub-id-type="doi">10.1210/me.2013-1213</pub-id><pub-id pub-id-type="pmid">24801505</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grasso</surname><given-names>CS</given-names></name><name><surname>Wu</surname><given-names>Y-M</given-names></name><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Khan</surname><given-names>AP</given-names></name><name><surname>Quist</surname><given-names>MJ</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Brenner</surname><given-names>JC</given-names></name><name><surname>Asangani</surname><given-names>IA</given-names></name><name><surname>Ateeq</surname><given-names>B</given-names></name><name><surname>Chun</surname><given-names>SY</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Sam</surname><given-names>L</given-names></name><name><surname>Anstett</surname><given-names>M</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Palanisamy</surname><given-names>N</given-names></name><name><surname>Ryslik</surname><given-names>GA</given-names></name><name><surname>Vandin</surname><given-names>F</given-names></name><name><surname>Raphael</surname><given-names>BJ</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Rhodes</surname><given-names>DR</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The mutational landscape of lethal castration-resistant prostate cancer</article-title><source>Nature</source><volume>487</volume><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1038/nature11125</pub-id><pub-id pub-id-type="pmid">22722839</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>GC</given-names></name><name><surname>Hwang</surname><given-names>J</given-names></name><name><surname>Wankowicz</surname><given-names>SAM</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Cibulskis</surname><given-names>C</given-names></name><name><surname>Gaviola</surname><given-names>GC</given-names></name><name><surname>Ghazikhanian</surname><given-names>V</given-names></name><name><surname>McKay</surname><given-names>RR</given-names></name><name><surname>Bubley</surname><given-names>GJ</given-names></name><name><surname>Carter</surname><given-names>SL</given-names></name><name><surname>Balk</surname><given-names>SP</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Taplin</surname><given-names>M-E</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer</article-title><source>JCO Precision Oncology</source><volume>1</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1200/PO.17.00140</pub-id><pub-id pub-id-type="pmid">32913968</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>CREB5 promotes tumor cell invasion and correlates with poor prognosis in epithelial ovarian cancer</article-title><source>Oncology Letters</source><volume>14</volume><fpage>8156</fpage><lpage>8161</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.7234</pub-id><pub-id pub-id-type="pmid">29250192</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>MX</given-names></name><name><surname>Cuoco</surname><given-names>MS</given-names></name><name><surname>Crowdis</surname><given-names>J</given-names></name><name><surname>Bosma-Moody</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Bi</surname><given-names>K</given-names></name><name><surname>Kanodia</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>M-J</given-names></name><name><surname>Ku</surname><given-names>S-Y</given-names></name><name><surname>Garcia</surname><given-names>MM</given-names></name><name><surname>Sweet</surname><given-names>AR</given-names></name><name><surname>Rodman</surname><given-names>C</given-names></name><name><surname>DelloStritto</surname><given-names>L</given-names></name><name><surname>Silver</surname><given-names>R</given-names></name><name><surname>Steinharter</surname><given-names>J</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Walk</surname><given-names>NC</given-names></name><name><surname>Burke</surname><given-names>KP</given-names></name><name><surname>Bakouny</surname><given-names>Z</given-names></name><name><surname>Tewari</surname><given-names>AK</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Camp</surname><given-names>SY</given-names></name><name><surname>Vokes</surname><given-names>NI</given-names></name><name><surname>Salari</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Vigneau</surname><given-names>S</given-names></name><name><surname>Fong</surname><given-names>L</given-names></name><name><surname>Russo</surname><given-names>JW</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Balk</surname><given-names>SP</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Rotem</surname><given-names>A</given-names></name><name><surname>Taplin</surname><given-names>M-E</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transcriptional mediators of treatment resistance in lethal prostate cancer</article-title><source>Nature Medicine</source><volume>27</volume><fpage>426</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01244-6</pub-id><pub-id pub-id-type="pmid">33664492</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname><given-names>S</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Spann</surname><given-names>N</given-names></name><name><surname>Bertolino</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Laslo</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>JX</given-names></name><name><surname>Murre</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title><source>Molecular Cell</source><volume>38</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.004</pub-id><pub-id pub-id-type="pmid">20513432</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henzler</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>McBride</surname><given-names>T</given-names></name><name><surname>Ho</surname><given-names>Y</given-names></name><name><surname>Sprenger</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Coleman</surname><given-names>I</given-names></name><name><surname>Lakely</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Landman</surname><given-names>SR</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Hwang</surname><given-names>TH</given-names></name><name><surname>Raj</surname><given-names>GV</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Plymate</surname><given-names>SR</given-names></name><name><surname>Dehm</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>13668</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13668</pub-id><pub-id pub-id-type="pmid">27897170</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>AL</given-names></name><name><surname>Tseng</surname><given-names>Y-Y</given-names></name><name><surname>Wala</surname><given-names>JA</given-names></name><name><surname>Kim</surname><given-names>W-J</given-names></name><name><surname>Kynnap</surname><given-names>BD</given-names></name><name><surname>Doshi</surname><given-names>MB</given-names></name><name><surname>Kugener</surname><given-names>G</given-names></name><name><surname>Sandoval</surname><given-names>GJ</given-names></name><name><surname>Howard</surname><given-names>TP</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Tillgren</surname><given-names>M</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Sayeed</surname><given-names>A</given-names></name><name><surname>Deasy</surname><given-names>R</given-names></name><name><surname>Ward</surname><given-names>A</given-names></name><name><surname>McSteen</surname><given-names>B</given-names></name><name><surname>Labella</surname><given-names>KM</given-names></name><name><surname>Keskula</surname><given-names>P</given-names></name><name><surname>Tracy</surname><given-names>A</given-names></name><name><surname>Connor</surname><given-names>C</given-names></name><name><surname>Clinton</surname><given-names>CM</given-names></name><name><surname>Church</surname><given-names>AJ</given-names></name><name><surname>Crompton</surname><given-names>BD</given-names></name><name><surname>Janeway</surname><given-names>KA</given-names></name><name><surname>Van Hare</surname><given-names>B</given-names></name><name><surname>Sandak</surname><given-names>D</given-names></name><name><surname>Gjoerup</surname><given-names>O</given-names></name><name><surname>Bandopadhayay</surname><given-names>P</given-names></name><name><surname>Clemons</surname><given-names>PA</given-names></name><name><surname>Schreiber</surname><given-names>SL</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Gokhale</surname><given-names>PC</given-names></name><name><surname>Chi</surname><given-names>SN</given-names></name><name><surname>Mullen</surname><given-names>EA</given-names></name><name><surname>Roberts</surname><given-names>CW</given-names></name><name><surname>Kadoch</surname><given-names>C</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Ligon</surname><given-names>KL</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Renal medullary carcinomas depend upon <italic>SMARCB1</italic> loss and are sensitive to proteasome inhibition</article-title><source>eLife</source><volume>8</volume><elocation-id>e44161</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.44161</pub-id><pub-id pub-id-type="pmid">30860482</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>TP</given-names></name><name><surname>Arnoff</surname><given-names>TE</given-names></name><name><surname>Song</surname><given-names>MR</given-names></name><name><surname>Giacomelli</surname><given-names>AO</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>AL</given-names></name><name><surname>Dharia</surname><given-names>NV</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Pham</surname><given-names>MT</given-names></name><name><surname>Morgan</surname><given-names>AM</given-names></name><name><surname>Wachter</surname><given-names>F</given-names></name><name><surname>Bird</surname><given-names>GH</given-names></name><name><surname>Kugener</surname><given-names>G</given-names></name><name><surname>Oberlick</surname><given-names>EM</given-names></name><name><surname>Rees</surname><given-names>MG</given-names></name><name><surname>Tiv</surname><given-names>HL</given-names></name><name><surname>Hwang</surname><given-names>JH</given-names></name><name><surname>Walsh</surname><given-names>KH</given-names></name><name><surname>Cook</surname><given-names>A</given-names></name><name><surname>Krill-Burger</surname><given-names>JM</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Gokhale</surname><given-names>PC</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Stegmaier</surname><given-names>K</given-names></name><name><surname>Walensky</surname><given-names>LD</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Roberts</surname><given-names>CWM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors</article-title><source>Cancer Research</source><volume>79</volume><fpage>2404</fpage><lpage>2414</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3066</pub-id><pub-id pub-id-type="pmid">30755442</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>JH</given-names></name><name><surname>Seo</surname><given-names>J-H</given-names></name><name><surname>Beshiri</surname><given-names>ML</given-names></name><name><surname>Wankowicz</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Cheung</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>AL</given-names></name><name><surname>Botta</surname><given-names>G</given-names></name><name><surname>Golumb</surname><given-names>L</given-names></name><name><surname>Richter</surname><given-names>C</given-names></name><name><surname>So</surname><given-names>J</given-names></name><name><surname>Sandoval</surname><given-names>GJ</given-names></name><name><surname>Giacomelli</surname><given-names>AO</given-names></name><name><surname>Ly</surname><given-names>SH</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><name><surname>Pakula</surname><given-names>H</given-names></name><name><surname>Sheahan</surname><given-names>A</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Gjoerup</surname><given-names>O</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Sowalsky</surname><given-names>AG</given-names></name><name><surname>Ellis</surname><given-names>L</given-names></name><name><surname>Long</surname><given-names>H</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Kelly</surname><given-names>K</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name><name><surname>Choudhury</surname><given-names>AD</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer</article-title><source>Cell Reports</source><volume>29</volume><fpage>2355</fpage><lpage>2370</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.10.068</pub-id><pub-id pub-id-type="pmid">31747605</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isaacsson Velho</surname><given-names>P</given-names></name><name><surname>Fu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Mirkheshti</surname><given-names>N</given-names></name><name><surname>Qazi</surname><given-names>F</given-names></name><name><surname>Lima</surname><given-names>FAS</given-names></name><name><surname>Shaukat</surname><given-names>F</given-names></name><name><surname>Carducci</surname><given-names>MA</given-names></name><name><surname>Denmeade</surname><given-names>SR</given-names></name><name><surname>Paller</surname><given-names>CJ</given-names></name><name><surname>Markowski</surname><given-names>MC</given-names></name><name><surname>Marshall</surname><given-names>CH</given-names></name><name><surname>Eisenberger</surname><given-names>MA</given-names></name><name><surname>Antonarakis</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer</article-title><source>European Urology</source><volume>77</volume><fpage>14</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2019.05.032</pub-id><pub-id pub-id-type="pmid">31176623</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Garcia</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>de la Cruz</surname><given-names>C</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name><name><surname>Merchant</surname><given-names>M</given-names></name><name><surname>Kharbanda</surname><given-names>S</given-names></name><name><surname>Raisner</surname><given-names>R</given-names></name><name><surname>Haverty</surname><given-names>PM</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Ly</surname><given-names>J</given-names></name><name><surname>Choo</surname><given-names>E</given-names></name><name><surname>Kaufman</surname><given-names>S</given-names></name><name><surname>Beresini</surname><given-names>MH</given-names></name><name><surname>Romero</surname><given-names>FA</given-names></name><name><surname>Magnuson</surname><given-names>S</given-names></name><name><surname>Gascoigne</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer</article-title><source>Cancer Research</source><volume>77</volume><fpage>5564</fpage><lpage>5575</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0314</pub-id><pub-id pub-id-type="pmid">28819026</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Rabinovic</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Adjusting batch effects in microarray expression data using empirical Bayes methods</article-title><source>Biostatistics (Oxford, England)</source><volume>8</volume><fpage>118</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1093/biostatistics/kxj037</pub-id><pub-id pub-id-type="pmid">16632515</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kregel</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>JL</given-names></name><name><surname>Tom</surname><given-names>W</given-names></name><name><surname>Krishnan</surname><given-names>V</given-names></name><name><surname>Kach</surname><given-names>J</given-names></name><name><surname>Brechka</surname><given-names>H</given-names></name><name><surname>Fessenden</surname><given-names>TB</given-names></name><name><surname>Isikbay</surname><given-names>M</given-names></name><name><surname>Paner</surname><given-names>GP</given-names></name><name><surname>Szmulewitz</surname><given-names>RZ</given-names></name><name><surname>Vander Griend</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer</article-title><source>Oncotarget</source><volume>7</volume><fpage>26259</fpage><lpage>26274</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8456</pub-id><pub-id pub-id-type="pmid">27036029</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krstic</surname><given-names>M</given-names></name><name><surname>Macmillan</surname><given-names>CD</given-names></name><name><surname>Leong</surname><given-names>HS</given-names></name><name><surname>Clifford</surname><given-names>AG</given-names></name><name><surname>Souter</surname><given-names>LH</given-names></name><name><surname>Dales</surname><given-names>DW</given-names></name><name><surname>Postenka</surname><given-names>CO</given-names></name><name><surname>Chambers</surname><given-names>AF</given-names></name><name><surname>Tuck</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer</article-title><source>BMC Cancer</source><volume>16</volume><elocation-id>671</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-016-2697-z</pub-id><pub-id pub-id-type="pmid">27553211</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuleshov</surname><given-names>MV</given-names></name><name><surname>Jones</surname><given-names>MR</given-names></name><name><surname>Rouillard</surname><given-names>AD</given-names></name><name><surname>Fernandez</surname><given-names>NF</given-names></name><name><surname>Duan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Koplev</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>SL</given-names></name><name><surname>Jagodnik</surname><given-names>KM</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>McDermott</surname><given-names>MG</given-names></name><name><surname>Monteiro</surname><given-names>CD</given-names></name><name><surname>Gundersen</surname><given-names>GW</given-names></name><name><surname>Ma’ayan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enrichr: a comprehensive gene set enrichment analysis web server 2016 update</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>W90</fpage><lpage>W97</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id><pub-id pub-id-type="pmid">27141961</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasko</surname><given-names>LM</given-names></name><name><surname>Jakob</surname><given-names>CG</given-names></name><name><surname>Edalji</surname><given-names>RP</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><name><surname>Montgomery</surname><given-names>D</given-names></name><name><surname>Digiammarino</surname><given-names>EL</given-names></name><name><surname>Hansen</surname><given-names>TM</given-names></name><name><surname>Risi</surname><given-names>RM</given-names></name><name><surname>Frey</surname><given-names>R</given-names></name><name><surname>Manaves</surname><given-names>V</given-names></name><name><surname>Shaw</surname><given-names>B</given-names></name><name><surname>Algire</surname><given-names>M</given-names></name><name><surname>Hessler</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>LT</given-names></name><name><surname>Uziel</surname><given-names>T</given-names></name><name><surname>Faivre</surname><given-names>E</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Buchanan</surname><given-names>FG</given-names></name><name><surname>Martin</surname><given-names>RL</given-names></name><name><surname>Torrent</surname><given-names>M</given-names></name><name><surname>Chiang</surname><given-names>GG</given-names></name><name><surname>Karukurichi</surname><given-names>K</given-names></name><name><surname>Langston</surname><given-names>JW</given-names></name><name><surname>Weinert</surname><given-names>BT</given-names></name><name><surname>Choudhary</surname><given-names>C</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>Van Drie</surname><given-names>JH</given-names></name><name><surname>McElligott</surname><given-names>D</given-names></name><name><surname>Kesicki</surname><given-names>E</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name><name><surname>Rosenberg</surname><given-names>SH</given-names></name><name><surname>Michaelides</surname><given-names>MR</given-names></name><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Bromberg</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours</article-title><source>Nature</source><volume>550</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/nature24028</pub-id><pub-id pub-id-type="pmid">28953875</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Launonen</surname><given-names>K-M</given-names></name><name><surname>Paakinaho</surname><given-names>V</given-names></name><name><surname>Sigismondo</surname><given-names>G</given-names></name><name><surname>Malinen</surname><given-names>M</given-names></name><name><surname>Sironen</surname><given-names>R</given-names></name><name><surname>Hartikainen</surname><given-names>JM</given-names></name><name><surname>Laakso</surname><given-names>H</given-names></name><name><surname>Visakorpi</surname><given-names>T</given-names></name><name><surname>Krijgsveld</surname><given-names>J</given-names></name><name><surname>Niskanen</surname><given-names>EA</given-names></name><name><surname>Palvimo</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells</article-title><source>Oncogene</source><volume>40</volume><fpage>4567</fpage><lpage>4579</lpage><pub-id pub-id-type="doi">10.1038/s41388-021-01887-2</pub-id><pub-id pub-id-type="pmid">34127815</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Layer</surname><given-names>RM</given-names></name><name><surname>Pedersen</surname><given-names>BS</given-names></name><name><surname>DiSera</surname><given-names>T</given-names></name><name><surname>Marth</surname><given-names>GT</given-names></name><name><surname>Gertz</surname><given-names>J</given-names></name><name><surname>Quinlan</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>GIGGLE: a search engine for large-scale integrated genome analysis</article-title><source>Nature Methods</source><volume>15</volume><fpage>123</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4556</pub-id><pub-id pub-id-type="pmid">29309061</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Ha</surname><given-names>S</given-names></name><name><surname>Logan</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0141589</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0141589</pub-id><pub-id pub-id-type="pmid">26509262</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leek</surname><given-names>JT</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Parker</surname><given-names>HS</given-names></name><name><surname>Jaffe</surname><given-names>AE</given-names></name><name><surname>Storey</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The sva package for removing batch effects and other unwanted variation in high-throughput experiments</article-title><source>Bioinformatics (Oxford, England)</source><volume>28</volume><fpage>882</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts034</pub-id><pub-id pub-id-type="pmid">22257669</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Q</given-names></name><name><surname>Viste</surname><given-names>K</given-names></name><name><surname>Urday-Zaa</surname><given-names>JC</given-names></name><name><surname>Senthil Kumar</surname><given-names>G</given-names></name><name><surname>Tsai</surname><given-names>WW</given-names></name><name><surname>Talai</surname><given-names>A</given-names></name><name><surname>Mayo</surname><given-names>KE</given-names></name><name><surname>Montminy</surname><given-names>M</given-names></name><name><surname>Radhakrishnan</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mechanism of CREB recognition and coactivation by the CREB-regulated transcriptional coactivator CRTC2</article-title><source>PNAS</source><volume>109</volume><fpage>20865</fpage><lpage>20870</lpage><pub-id pub-id-type="doi">10.1073/pnas.1219028109</pub-id><pub-id pub-id-type="pmid">23213254</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>TW</given-names></name><name><surname>Link</surname><given-names>KA</given-names></name><name><surname>Petre-Draviam</surname><given-names>CE</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Differential requirement of SWI/SNF for androgen receptor activity</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>30605</fpage><lpage>30613</lpage><pub-id pub-id-type="doi">10.1074/jbc.M304582200</pub-id><pub-id pub-id-type="pmid">12775722</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>H</given-names></name><name><surname>Taylor</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><name><surname>Papachristou</surname><given-names>EK</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>D’Santos</surname><given-names>CS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Rapid immunoprecipitation mass spectrometry of endogenous proteins (RIME) for analysis of chromatin complexes</article-title><source>Nature Protocols</source><volume>11</volume><fpage>316</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/nprot.2016.020</pub-id><pub-id pub-id-type="pmid">26797456</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molnár</surname><given-names>B</given-names></name><name><surname>Galamb</surname><given-names>O</given-names></name><name><surname>Péterfia</surname><given-names>B</given-names></name><name><surname>Wichmann</surname><given-names>B</given-names></name><name><surname>Csabai</surname><given-names>I</given-names></name><name><surname>Bodor</surname><given-names>A</given-names></name><name><surname>Kalmár</surname><given-names>A</given-names></name><name><surname>Szigeti</surname><given-names>KA</given-names></name><name><surname>Barták</surname><given-names>BK</given-names></name><name><surname>Nagy</surname><given-names>ZB</given-names></name><name><surname>Valcz</surname><given-names>G</given-names></name><name><surname>Patai</surname><given-names>ÁV</given-names></name><name><surname>Igaz</surname><given-names>P</given-names></name><name><surname>Tulassay</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Gene promoter and exon DNA methylation changes in colon cancer development - mRNA expression and tumor mutation alterations</article-title><source>BMC Cancer</source><volume>18</volume><elocation-id>695</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-018-4609-x</pub-id><pub-id pub-id-type="pmid">29945573</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murillo-Garzón</surname><given-names>V</given-names></name><name><surname>Kypta</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>WNT signalling in prostate cancer</article-title><source>Nature Reviews. Urology</source><volume>14</volume><fpage>683</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2017.144</pub-id><pub-id pub-id-type="pmid">28895566</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakshatri</surname><given-names>H</given-names></name><name><surname>Badve</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>FOXA1 in breast cancer</article-title><source>Expert Reviews in Molecular Medicine</source><volume>11</volume><elocation-id>e8</elocation-id><pub-id pub-id-type="doi">10.1017/S1462399409001008</pub-id><pub-id pub-id-type="pmid">19261198</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>HM</given-names></name><name><surname>Vessella</surname><given-names>RL</given-names></name><name><surname>Morrissey</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>LG</given-names></name><name><surname>Coleman</surname><given-names>IM</given-names></name><name><surname>Higano</surname><given-names>CS</given-names></name><name><surname>Mostaghel</surname><given-names>EA</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Lam</surname><given-names>H-M</given-names></name><name><surname>Roudier</surname><given-names>M</given-names></name><name><surname>Lange</surname><given-names>PH</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics</article-title><source>The Prostate</source><volume>77</volume><fpage>654</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1002/pros.23313</pub-id><pub-id pub-id-type="pmid">28156002</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nomura</surname><given-names>N</given-names></name><name><surname>Zu</surname><given-names>YL</given-names></name><name><surname>Maekawa</surname><given-names>T</given-names></name><name><surname>Tabata</surname><given-names>S</given-names></name><name><surname>Akiyama</surname><given-names>T</given-names></name><name><surname>Ishii</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Isolation and characterization of a novel member of the gene family encoding the cAMP response element-binding protein CRE-BP1</article-title><source>The Journal of Biological Chemistry</source><volume>268</volume><fpage>4259</fpage><lpage>4266</lpage><pub-id pub-id-type="pmid">8440710</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paltoglou</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Townley</surname><given-names>SL</given-names></name><name><surname>Hickey</surname><given-names>TE</given-names></name><name><surname>Tarulli</surname><given-names>GA</given-names></name><name><surname>Coutinho</surname><given-names>I</given-names></name><name><surname>Fernandes</surname><given-names>R</given-names></name><name><surname>Hanson</surname><given-names>AR</given-names></name><name><surname>Denis</surname><given-names>I</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Dehm</surname><given-names>SM</given-names></name><name><surname>Raj</surname><given-names>GV</given-names></name><name><surname>Plymate</surname><given-names>SR</given-names></name><name><surname>Tilley</surname><given-names>WD</given-names></name><name><surname>Selth</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate Cancer</article-title><source>Cancer Research</source><volume>77</volume><fpage>3417</fpage><lpage>3430</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-1616</pub-id><pub-id pub-id-type="pmid">28473532</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parolia</surname><given-names>A</given-names></name><name><surname>Cieslik</surname><given-names>M</given-names></name><name><surname>Chu</surname><given-names>S-C</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Ouchi</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Pitchiaya</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Wu</surname><given-names>Y-M</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer</article-title><source>Nature</source><volume>571</volume><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1347-4</pub-id><pub-id pub-id-type="pmid">31243372</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Proteomics: the move to mixtures</article-title><source>Journal of Mass Spectrometry</source><volume>36</volume><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1002/jms.229</pub-id><pub-id pub-id-type="pmid">11747101</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomerantz</surname><given-names>MM</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Takeda</surname><given-names>DY</given-names></name><name><surname>Lenci</surname><given-names>R</given-names></name><name><surname>Chonkar</surname><given-names>A</given-names></name><name><surname>Chabot</surname><given-names>M</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Cook</surname><given-names>J</given-names></name><name><surname>Shivdasani</surname><given-names>RA</given-names></name><name><surname>Bowden</surname><given-names>M</given-names></name><name><surname>Lis</surname><given-names>R</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Long</surname><given-names>HW</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1346</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1038/ng.3419</pub-id><pub-id pub-id-type="pmid">26457646</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pomerantz</surname><given-names>MM</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>DY</given-names></name><name><surname>Pan</surname><given-names>W</given-names></name><name><surname>Baca</surname><given-names>SC</given-names></name><name><surname>Gusev</surname><given-names>A</given-names></name><name><surname>Korthauer</surname><given-names>KD</given-names></name><name><surname>Severson</surname><given-names>TM</given-names></name><name><surname>Ha</surname><given-names>G</given-names></name><name><surname>Viswanathan</surname><given-names>SR</given-names></name><name><surname>Seo</surname><given-names>J-H</given-names></name><name><surname>Nguyen</surname><given-names>HM</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Pasaniuc</surname><given-names>B</given-names></name><name><surname>Giambartolomei</surname><given-names>C</given-names></name><name><surname>Alaiwi</surname><given-names>SA</given-names></name><name><surname>Bell</surname><given-names>CA</given-names></name><name><surname>O’Connor</surname><given-names>EP</given-names></name><name><surname>Chabot</surname><given-names>MS</given-names></name><name><surname>Stillman</surname><given-names>DR</given-names></name><name><surname>Lis</surname><given-names>R</given-names></name><name><surname>Font-Tello</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Bergman</surname><given-names>AM</given-names></name><name><surname>Sanders</surname><given-names>J</given-names></name><name><surname>van der Poel</surname><given-names>HG</given-names></name><name><surname>Gayther</surname><given-names>SA</given-names></name><name><surname>Lawrenson</surname><given-names>K</given-names></name><name><surname>Fonseca</surname><given-names>MAS</given-names></name><name><surname>Reddy</surname><given-names>J</given-names></name><name><surname>Corona</surname><given-names>RI</given-names></name><name><surname>Martovetsky</surname><given-names>G</given-names></name><name><surname>Egan</surname><given-names>B</given-names></name><name><surname>Choueiri</surname><given-names>T</given-names></name><name><surname>Ellis</surname><given-names>L</given-names></name><name><surname>Garraway</surname><given-names>IP</given-names></name><name><surname>Lee</surname><given-names>G-SM</given-names></name><name><surname>Corey</surname><given-names>E</given-names></name><name><surname>Long</surname><given-names>HW</given-names></name><name><surname>Zwart</surname><given-names>W</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Prostate cancer reactivates developmental epigenomic programs during metastatic progression</article-title><source>Nature Genetics</source><volume>52</volume><fpage>790</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-0664-8</pub-id><pub-id pub-id-type="pmid">32690948</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Involvement of the CREB5 regulatory network in colorectal cancer metastasis</article-title><source>Yi Chuan = Hereditas</source><volume>36</volume><fpage>679</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.3724/SP.J.1005.2014.0679</pub-id><pub-id pub-id-type="pmid">25076032</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinlan</surname><given-names>AR</given-names></name><name><surname>Hall</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BEDTools: a flexible suite of utilities for comparing genomic features</article-title><source>Bioinformatics (Oxford, England)</source><volume>26</volume><fpage>841</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq033</pub-id><pub-id pub-id-type="pmid">20110278</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>D</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Wu</surname><given-names>Y-M</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Mosquera</surname><given-names>J-M</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Taplin</surname><given-names>M-E</given-names></name><name><surname>Pritchard</surname><given-names>CC</given-names></name><name><surname>Attard</surname><given-names>G</given-names></name><name><surname>Beltran</surname><given-names>H</given-names></name><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Bradley</surname><given-names>RK</given-names></name><name><surname>Vinson</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Tomlins</surname><given-names>SA</given-names></name><name><surname>Cooney</surname><given-names>KA</given-names></name><name><surname>Smith</surname><given-names>DC</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><name><surname>Siddiqui</surname><given-names>J</given-names></name><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Rathkopf</surname><given-names>DE</given-names></name><name><surname>Morris</surname><given-names>MJ</given-names></name><name><surname>Solomon</surname><given-names>SB</given-names></name><name><surname>Durack</surname><given-names>JC</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Loda</surname><given-names>M</given-names></name><name><surname>Lis</surname><given-names>RT</given-names></name><name><surname>Bowden</surname><given-names>M</given-names></name><name><surname>Balk</surname><given-names>SP</given-names></name><name><surname>Gaviola</surname><given-names>G</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>EY</given-names></name><name><surname>Mostaghel</surname><given-names>EA</given-names></name><name><surname>Cheng</surname><given-names>HH</given-names></name><name><surname>Mulcahy</surname><given-names>H</given-names></name><name><surname>True</surname><given-names>LD</given-names></name><name><surname>Plymate</surname><given-names>SR</given-names></name><name><surname>Dvinge</surname><given-names>H</given-names></name><name><surname>Ferraldeschi</surname><given-names>R</given-names></name><name><surname>Flohr</surname><given-names>P</given-names></name><name><surname>Miranda</surname><given-names>S</given-names></name><name><surname>Zafeiriou</surname><given-names>Z</given-names></name><name><surname>Tunariu</surname><given-names>N</given-names></name><name><surname>Mateo</surname><given-names>J</given-names></name><name><surname>Perez-Lopez</surname><given-names>R</given-names></name><name><surname>Demichelis</surname><given-names>F</given-names></name><name><surname>Robinson</surname><given-names>BD</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Schiffman</surname><given-names>M</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name><name><surname>Tagawa</surname><given-names>ST</given-names></name><name><surname>Sigaras</surname><given-names>A</given-names></name><name><surname>Eng</surname><given-names>KW</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Sboner</surname><given-names>A</given-names></name><name><surname>Heath</surname><given-names>EI</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Pienta</surname><given-names>KJ</given-names></name><name><surname>Kantoff</surname><given-names>P</given-names></name><name><surname>de Bono</surname><given-names>JS</given-names></name><name><surname>Rubin</surname><given-names>MA</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integrative Clinical Genomics of Advanced Prostate Cancer</article-title><source>Cell</source><volume>162</volume><elocation-id>454</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2015.06.053</pub-id><pub-id pub-id-type="pmid">28843286</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Sly Oncogene: FOXA1 Mutations in Prostate Cancer</article-title><source>Cancer Cell</source><volume>36</volume><fpage>119</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.07.005</pub-id><pub-id pub-id-type="pmid">31408618</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shalem</surname><given-names>O</given-names></name><name><surname>Sanjana</surname><given-names>NE</given-names></name><name><surname>Hartenian</surname><given-names>E</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Mikkelson</surname><given-names>T</given-names></name><name><surname>Heckl</surname><given-names>D</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome-scale CRISPR-Cas9 knockout screening in human cells</article-title><source>Science (New York, N.Y.)</source><volume>343</volume><fpage>84</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1126/science.1247005</pub-id><pub-id pub-id-type="pmid">24336571</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>NL</given-names></name><name><surname>Massie</surname><given-names>CE</given-names></name><name><surname>Ramos-Montoya</surname><given-names>A</given-names></name><name><surname>Zecchini</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>HE</given-names></name><name><surname>Lamb</surname><given-names>AD</given-names></name><name><surname>MacArthur</surname><given-names>S</given-names></name><name><surname>Stark</surname><given-names>R</given-names></name><name><surname>Warren</surname><given-names>AY</given-names></name><name><surname>Mills</surname><given-names>IG</given-names></name><name><surname>Neal</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man</article-title><source>Cancer Cell</source><volume>23</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.11.010</pub-id><pub-id pub-id-type="pmid">23260764</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shevchenko</surname><given-names>A</given-names></name><name><surname>Wilm</surname><given-names>M</given-names></name><name><surname>Vorm</surname><given-names>O</given-names></name><name><surname>Mann</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels</article-title><source>Analytical Chemistry</source><volume>68</volume><fpage>850</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1021/ac950914h</pub-id><pub-id pub-id-type="pmid">8779443</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>V</given-names></name><name><surname>Livingstone</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Fox</surname><given-names>NS</given-names></name><name><surname>Kurganovs</surname><given-names>N</given-names></name><name><surname>Ignatchenko</surname><given-names>V</given-names></name><name><surname>Fritsch</surname><given-names>K</given-names></name><name><surname>Donmez</surname><given-names>N</given-names></name><name><surname>Heisler</surname><given-names>LE</given-names></name><name><surname>Shiah</surname><given-names>Y-J</given-names></name><name><surname>Yao</surname><given-names>CQ</given-names></name><name><surname>Alfaro</surname><given-names>JA</given-names></name><name><surname>Volik</surname><given-names>S</given-names></name><name><surname>Lapuk</surname><given-names>A</given-names></name><name><surname>Fraser</surname><given-names>M</given-names></name><name><surname>Kron</surname><given-names>K</given-names></name><name><surname>Murison</surname><given-names>A</given-names></name><name><surname>Lupien</surname><given-names>M</given-names></name><name><surname>Sahinalp</surname><given-names>C</given-names></name><name><surname>Collins</surname><given-names>CC</given-names></name><name><surname>Tetu</surname><given-names>B</given-names></name><name><surname>Masoomian</surname><given-names>M</given-names></name><name><surname>Berman</surname><given-names>DM</given-names></name><name><surname>van der Kwast</surname><given-names>T</given-names></name><name><surname>Bristow</surname><given-names>RG</given-names></name><name><surname>Kislinger</surname><given-names>T</given-names></name><name><surname>Boutros</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The Proteogenomic Landscape of Curable Prostate Cancer</article-title><source>Cancer Cell</source><volume>35</volume><fpage>414</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.02.005</pub-id><pub-id pub-id-type="pmid">30889379</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>DY</given-names></name><name><surname>Spisák</surname><given-names>S</given-names></name><name><surname>Seo</surname><given-names>J-H</given-names></name><name><surname>Bell</surname><given-names>C</given-names></name><name><surname>O’Connor</surname><given-names>E</given-names></name><name><surname>Korthauer</surname><given-names>K</given-names></name><name><surname>Ribli</surname><given-names>D</given-names></name><name><surname>Csabai</surname><given-names>I</given-names></name><name><surname>Solymosi</surname><given-names>N</given-names></name><name><surname>Szállási</surname><given-names>Z</given-names></name><name><surname>Stillman</surname><given-names>DR</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Long</surname><given-names>HW</given-names></name><name><surname>Tisza</surname><given-names>V</given-names></name><name><surname>Nuzzo</surname><given-names>PV</given-names></name><name><surname>Rohanizadegan</surname><given-names>M</given-names></name><name><surname>Pomerantz</surname><given-names>MM</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A Somatically Acquired Enhancer of the Androgen Receptor Is A Noncoding Driver in Advanced Prostate Cancer</article-title><source>Cell</source><volume>174</volume><fpage>422</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.05.037</pub-id><pub-id pub-id-type="pmid">29909987</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Montgomery</surname><given-names>PG</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Kryukov</surname><given-names>G</given-names></name><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Harrington</surname><given-names>WF</given-names></name><name><surname>Pantel</surname><given-names>S</given-names></name><name><surname>Krill-Burger</surname><given-names>JM</given-names></name><name><surname>Meyers</surname><given-names>RM</given-names></name><name><surname>Ali</surname><given-names>L</given-names></name><name><surname>Goodale</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Gerath</surname><given-names>WFJ</given-names></name><name><surname>Howell</surname><given-names>S</given-names></name><name><surname>Merkel</surname><given-names>E</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defining a Cancer Dependency Map</article-title><source>Cell</source><volume>170</volume><fpage>564</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id><pub-id pub-id-type="pmid">28753430</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viswanathan</surname><given-names>SR</given-names></name><name><surname>Ha</surname><given-names>G</given-names></name><name><surname>Hoff</surname><given-names>AM</given-names></name><name><surname>Wala</surname><given-names>JA</given-names></name><name><surname>Carrot-Zhang</surname><given-names>J</given-names></name><name><surname>Whelan</surname><given-names>CW</given-names></name><name><surname>Haradhvala</surname><given-names>NJ</given-names></name><name><surname>Freeman</surname><given-names>SS</given-names></name><name><surname>Reed</surname><given-names>SC</given-names></name><name><surname>Rhoades</surname><given-names>J</given-names></name><name><surname>Polak</surname><given-names>P</given-names></name><name><surname>Cipicchio</surname><given-names>M</given-names></name><name><surname>Wankowicz</surname><given-names>SA</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Kamath</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Gydush</surname><given-names>GJ</given-names></name><name><surname>Rotem</surname><given-names>D</given-names></name><collab>PCF/SU2C International Prostate Cancer Dream Team</collab><name><surname>Love</surname><given-names>JC</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C-Z</given-names></name><name><surname>Dehm</surname><given-names>SM</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Choudhury</surname><given-names>AD</given-names></name><name><surname>Adalsteinsson</surname><given-names>VA</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Taplin</surname><given-names>M-E</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing</article-title><source>Cell</source><volume>174</volume><fpage>433</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.05.036</pub-id><pub-id pub-id-type="pmid">29909985</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welti</surname><given-names>J</given-names></name><name><surname>Sharp</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>N</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>McNair</surname><given-names>C</given-names></name><name><surname>Chand</surname><given-names>SN</given-names></name><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Figueiredo</surname><given-names>I</given-names></name><name><surname>Riisnaes</surname><given-names>R</given-names></name><name><surname>Gurel</surname><given-names>B</given-names></name><name><surname>Rekowski</surname><given-names>J</given-names></name><name><surname>Bogdan</surname><given-names>D</given-names></name><name><surname>West</surname><given-names>W</given-names></name><name><surname>Young</surname><given-names>B</given-names></name><name><surname>Raja</surname><given-names>M</given-names></name><name><surname>Prosser</surname><given-names>A</given-names></name><name><surname>Lane</surname><given-names>J</given-names></name><name><surname>Thomson</surname><given-names>S</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><name><surname>Onions</surname><given-names>S</given-names></name><name><surname>Shannon</surname><given-names>J</given-names></name><name><surname>Paoletta</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>R</given-names></name><name><surname>Smyth</surname><given-names>D</given-names></name><name><surname>Harbottle</surname><given-names>GW</given-names></name><name><surname>Gil</surname><given-names>VS</given-names></name><name><surname>Miranda</surname><given-names>S</given-names></name><name><surname>Crespo</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name><name><surname>Pereira</surname><given-names>R</given-names></name><name><surname>Tunariu</surname><given-names>N</given-names></name><name><surname>Carreira</surname><given-names>S</given-names></name><name><surname>Neeb</surname><given-names>AJ</given-names></name><name><surname>Ning</surname><given-names>J</given-names></name><name><surname>Swain</surname><given-names>A</given-names></name><name><surname>Taddei</surname><given-names>D</given-names></name><collab>SU2C/PCF International Prostate Cancer Dream Team</collab><name><surname>Schiewer</surname><given-names>MJ</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name><name><surname>Pegg</surname><given-names>N</given-names></name><name><surname>de Bono</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Targeting the p300/CBP Axis in Lethal Prostate Cancer</article-title><source>Cancer Discovery</source><volume>11</volume><fpage>1118</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0751</pub-id><pub-id pub-id-type="pmid">33431496</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Yi</surname><given-names>P</given-names></name><name><surname>Hamilton</surname><given-names>RA</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Foulds</surname><given-names>CE</given-names></name><name><surname>Mancini</surname><given-names>MA</given-names></name><name><surname>Ludtke</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>O’Malley</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes</article-title><source>Molecular Cell</source><volume>79</volume><fpage>812</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.06.031</pub-id><pub-id pub-id-type="pmid">32668201</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73223.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sawyers</surname><given-names>Charles L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>Building on your earlier work implicating CREB5 in resistance to androgen receptor (AR) inhibition, you have now defined the CREB5 interactome in this setting, revealing physical interaction with AR, with the pioneer transcription factor FOXA1, and with other known co-interacting nuclear factors such as TBX3 and NFIC. Collectively, this work strengthens our understanding of how dysregulated epigenomic and transcriptomic processes drive disease pathogenesis and progression.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73223.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sawyers</surname><given-names>Charles L</given-names></name><role>Reviewing Editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for sending your article entitled &quot;CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapies&quot; for peer review at <italic>eLife</italic>. Your article is being evaluated by 2 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation is being overseen by Kathryn Cheah as the Senior Editor.</p><p>While both reviewers appreciate the work that went into defining the CREB5 cistrome and interactome, you will see two major concerns have been raised.</p><p>1. Reviewer 1 wants to understand whether CREB5 confers ART resistance by working through AR, by restoring/reshaping its function, versus a lineage plasticity model as suggested by enrichment of EMT/TGF-β signatures. This would require further experiments in CREB5 wild-type vs overexpression models and ideally other prostate models beyond LNCaP to address questions of generalizability.</p><p>2. Reviewer 2 raises concerns about the underlying premise of CREB5/AR biology based on literature data showing that CREB5 is an AR-repressed gene.</p><p><italic>Reviewer #1:</italic></p><p>Previously, these authors identified CREB5 overexpression as a mechanism that drives enzalutamide resistance, which they reported in <italic>eLife</italic>. In this paper, the authors use ChIP-seq and RIME to further characterize CREB5 in this context. The main findings are co-association/overlap of motifs and protein interactions with AR and FOXA1. Through mutagenesis of the known FOS/JUN interaction motif in CREB5 followed by addition RIME, the authors identify NFIC and TBX3 as additional interaction partners associated with enzalutamide resistance. Analysis of Achilles data and an enzalutamide-resistant LNCaP subline suggest dependencies in prostate cancer lines, similar to those seen with FOXA1. This work further develops the previously published CREB5 story and provides useful datasets on CREB5 binding sites and protein interaction partners, but the overall novelty and impact are limited.</p><p>Specific comments</p><p>1. The enrichment for signatures of EMT and TGF-β (Figure 5) is puzzling since lineage shifts of this type (away from luminal) is generally associated with loss of AR dependency. Yet the ChIP-seq and interactome data point to AR, FOXA1, etc as the primary drivers of CREB5 biology. How do the authors reconcile these findings? Does enzalutamide resistance mediated by CREB5 still require AR? (i.e., what happens with genetic ablation of AR?)</p><p>2. Figure 4B shows that both TBX3 and NFIC are required for cell viability in the LNCaP cells that spontaneously developed resistance to enzalutamide. This is the major novelty in the work but is only addressed in this one experiment. At a minimum, the authors should test the function of TBX3 and NFIC in a CREB5 overexpressing cell line because that is the biological context in which the screens were done. As with their earlier paper, it would also be more persuasive to conduct these experiments in vivo (e.g. using xenograft models) to show that TBX3 and NFIC are important regulators for castration + enzalutamide resistance. The in vivo experiment would also be a better context to address the potential lineage changes such as EMT (see comment #1).</p><p>3. Figure 4A plots the dependency results in prostate cancer cell lines from Project Achilles, noting that TBX3 and NFIC both score. Are all of these lines AR-positive? What about widely used AR-negative lines like PC3 and DU145? Also, how do TBX3 and NFIC score in a pan cancer analysis? And what are the results from DepMap?</p><p>4. In figure 3D, LDB1 and DNMT1 are another two proteins that have reduced binding with CREB5 mutants comparing with wildtype CREB5. The authors ignored these two proteins and focused on NFIC and TBX3. Why not examine all four? Do LDB1 and DNMT1 also play a role in ART resistance?</p><p>5. For the CREB5 binding proteins identified using RIME, especially the ART reprogrammed protein-protein interactions, the results would be more convincing if the authors could provide a few validations using co-immunoprecipitation (co-IP).</p><p>6. In my opinion, the title &quot;CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapies&quot; seems a bit misleading. The experiments and analysis focus on the effects of CREB5 in the presence of ART, which is already known to have a major impact on protein interactions and chromatin landscape.</p><p>The work needs to clarify whether the effects of CREB5 overexpression and the dependencies on TBX3 and NIFC are restricted to AR-positive/AR-dependent models.</p><p><italic>Reviewer #2:</italic></p><p>This reviewer acknowledges the tremendous effort that went into producing high-quality OMIC data. The authors were likely unaware that CREB5 was an AR target gene and if they confirm it to be so in their model system they will have to reformulate their hypothesis and completely rewrite the paper. Further, there are no data presented in this paper that shows that CREB5 is causally involved in processes that confer resistance to enzalutamide. They need to validate he results of the OMICs approaches with such studies.</p><p>1. The apparent goal of the ORF screen (described in figure 1) was to identify factors whose involvement in PCa pathobiology was dependent on ENZ. However, a quick review of several published RNAseq datasets indicates that CREB5 is highly downregulated in PCa cells (normal and malignant) treated with R1881, Enz or Bicalutamide (its also downregulated by agonist activated progesterone receptor in several systems). Have the authors considered that they may have identified a gene (CREB5) that is AR repressed that is important for AR action and that the protein is not specifically related to ENZ/ADT resistance but is required for AR action? The potential involvement of CREB in AR action more broadly needs to be probed, but this reviewer suspects that when explored further the authors will find that the protein is not involved in resistance-dependent reprogramming of the AR cistrome per se.</p><p>2. Given that CREB5 is highly downregulated in cells treated with R1881, Enz or Bicalutamide one interpretation of the authors findings is that overexpression of CREB5 bypasses this regulatory pathway but that should impact the activity of both agonists and antagonists. Thus, the authors need to consider that they may have identified a gene (CREB5) that is AR repressed that its reduced expression is important for AR action and that dysregulation of the expression of this protein is not specifically related to ENZ/ADT resistance? To support their specific hypothesis the authors would have to show that CREB5 overexpression has no effect on R1881 dependent transcription. Otherwise the focus of the paper must change completely to consider a more &quot;physiological&quot; role for CREB5 in AR action.</p><p>3. The appearance of FOXA1 GRHL2, FOXA1 et at CREB5 binding sites is interesting but the requirement for AR in these studies is not demonstrated.</p><p>4. In designing the screen the assumption is made that CSS is just FBS &quot;without androgens&quot; which is not the case. FBS +/- enz would seem to be a more relevant model to look for important mediators of resistance (enz is not very active in this scenario but that is another story!). Further, if androgens suppress CREB5 (as has been demonstrated) and this is required for proliferation then overexpression of CREB5 would bypass this regulation and thus would explain the results observed in FBS (inhibition of proliferation).</p><p>5. If CREB5 downregulation is required for normal AR function then it is hard to explain the dependencies highlighted in DEPMAP. Unless its overexpression prevents the repression/downregulation of proliferation that occurs in PCa cancer cells as androgen levels rise.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73223.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>Previously, these authors identified CREB5 overexpression as a mechanism that drives enzalutamide resistance, which they reported in eLife. In this paper, the authors use ChIP-seq and RIME to further characterize CREB5 in this context. The main findings are co-association/overlap of motifs and protein interactions with AR and FOXA1. Through mutagenesis of the known FOS/JUN interaction motif in CREB5 followed by addition RIME, the authors identify NFIC and TBX3 as additional interaction partners associated with enzalutamide resistance. Analysis of Achilles data and an enzalutamide-resistant LNCaP subline suggest dependencies in prostate cancer lines, similar to those seen with FOXA1. This work further develops the previously published CREB5 story and provides useful datasets on CREB5 binding sites and protein interaction partners, but the overall novelty and impact are limited.</p><p>Specific comments</p><p>1. The enrichment for signatures of EMT and TGF-β (Figure 5) is puzzling since lineage shifts of this type (away from luminal) is generally associated with loss of AR dependency. Yet the ChIP-seq and interactome data point to AR, FOXA1, etc as the primary drivers of CREB5 biology. How do the authors reconcile these findings? Does enzalutamide resistance mediated by CREB5 still require AR? (i.e., what happens with genetic ablation of AR?)</p></disp-quote><p>We agree with the Reviewer that initial studies suggested that EMT signaling or other lineage plastic pathways occurred after adenocarcinomas differentiated into AR independent states, including neuroendocrine prostate cancer (NEPC) (Beltran et al., Nat Med, 2016). However, genes implicated as part of the EMT pathway are also associated with numerous cancer processes other than plasticity observed in NEPC. Recent single-cell RNA sequencing studies (He et al., Nat Med, 2021) reported that increased EMT signaling co-occurs with increased levels of AR or various splice variants in biopsy-matched treatment-resistant adenocarcinoma samples. Upon further analysis of data from this study, we present the supporting evidence as <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>. These AR or AR spice variant expressing tumor cells did not exhibit a NEPC histology. In another independent study, several mCRPCs that developed enzalutamide resistance exhibited increased EMT signaling (Alumkal et al., Proc Natl Acad Sci U S A, 2020). These findings indicate that enzalutamide-resistant adenocarcinomas harbor a dependency on AR functions while also co-expressing markers consistent with EMT signaling, suggesting that enzalutamide resistance, loss of AR expression and EMT do not occur in a linear manner.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>A.</title><p>Figure adapted from He et al. (He et al., Nat Med, 2021). Single cells from a mCRPC patient pre- and post-treatment were examined based on single cell RNA-seq approach and the most enriched pathway was EMT after enzalutamide treatment. B. AR expression levels were examined in the sample tumor cells, which increased with statistical significance (Student’s t-test).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-sa2-fig1-v2.tif"/></fig><p>In examining CREB5 and its regulation of EMT signaling, we have previously conducted RNA-seq on LNCaP cells that overexpress control (luciferase) or CREB5. As part of this revision, we performed additional experiments to overexpress CREB5 in several additional cell models including the AR-dependent LAPC-4 cells and AR-negative PC3 and DU145 (discussed in Results, p. 7). We previously showed that CREB5 overexpression promoted enzalutamide resistance in the AR-positive LNCaP and LAPC-4 cells (Hwang et al., Cell Rep, 2019). Here we conducted RNA-seq on LAPC-4, PC3 and DU145 cells that overexpress a control vector or CREB5. We then took an unbiased GSEA approach to identify pathways that are associated with CREB5 overexpression in the two AR-positive cell lines and separately in 209 mCRPC samples. We found that CREB5 overexpression was significantly associated with enrichment of EMT signaling in the AR-positive LNCaP and LAPC4 cells, but not in the AR-negative cell lines PC3 and DU145 (updated Figure 6C, discussed in Results, p. 7). Furthermore, CREB5 expression correlated with EMT in the mCRPC samples (Figure 6D, discussed in Results, p. 7). In these analyses, TGF-β expression was not statistically significant in the AR-positive cell lines or mCRPC samples. Based on these new findings we have removed the references to TGF-Β signaling from this manuscript (Figure 6C, 6D). Collectively, these findings indicate that EMT occurs even in AR-dependent prostate tumors and that some enzalutamide resistant cancers remain dependent on AR signaling even in the midst of changes in differentiation state.</p><p>We found in our prior manuscript (Hwang et al., Cell Rep, 2019) that the genetic ablation of AR or FOXA1 reduced viability of CREB5 overexpressing cells. We also reported that CREB5 regulated AR binding in a subset of AR driven genes. As part of this revision, we have performed a new experiment in which we suppressed AR in CREB5 expressing cells, which confirmed that these cells require AR expression for cell fitness (now Figure 1 —figure supplement 1). Together, these observations implicate AR function as necessary for CREB5 driven prostate cancer cell survival.</p><p>The observations in our current manuscript indicate that CREB5 is one mechanism that may regulate a subset of co-factors and transcription targets of EMT while also retaining AR-dependency.</p><p><xref ref-type="fig" rid="sa2fig1">Author response image 1</xref> is provided but not included in the manuscript since it is analysis of published data. We have elaborated these points in the Discussion and the added Supplementary Figure 1 of the revised manuscript (p. 8).</p><disp-quote content-type="editor-comment"><p>2. Figure 4B shows that both TBX3 and NFIC are required for cell viability in the LNCaP cells that spontaneously developed resistance to enzalutamide. This is the major novelty in the work but is only addressed in this one experiment. At a minimum, the authors should test the function of TBX3 and NFIC in a CREB5 overexpressing cell line because that is the biological context in which the screens were done. As with their earlier paper, it would also be more persuasive to conduct these experiments in vivo (e.g. using xenograft models) to show that TBX3 and NFIC are important regulators for castration + enzalutamide resistance. The in vivo experiment would also be a better context to address the potential lineage changes such as EMT (see comment #1).</p></disp-quote><p>We thank the reviewer for this suggestion. We have now performed experiments in which we found that suppression of TBX3 or NFIC using 2 shRNAs, as compared to a negative control (GFP), reduced the viability of CREB5 overexpressing LNCaP cells in enzalutamide cultures to the same level as 2 positive control shRNAs that targeted FOXA1, the CREB5 co-factor. These observations indicate that TBX3 and NFIC, like FOXA1 are required for optimal viability of CREB5 cells in the presence of enzalutamide (now Figure 4C, discussed in Results, p. 6). In our original submission, we demonstrated the role of TBX3 and NFIC as a necessary regulator for cell fitness in one LNCaP cell line that spontaneously acquired resistance to enzalutamide after long term cultures in enzalutamide (Kregel et al., Oncotarget, 2016) (now Figure 4D, discussed in Results, p. 6, p. 7).</p><p>In addition, as part of this revision, we have partitioned results based on AR status of the prostate cancer cell lines (also see response to Reviewer 1, comment 3). When examining the relative dependencies of TBX3 and NFIC in the AR-positive cell lines, we found that relative to all genes, TBX3 and NFIC exhibited similar dependencies as FOXA1, a pan prostate cancer cell dependency (Pomerantz et al., Nat Genet, 2015). This observation supports the conclusion that TBX3 and NFIC regulate viability in the setting of AR (Figure 4A, and 4B, discussed in Results, p. 6).</p><p>As part of this revision, we also determined that CREB5 expression is associated with increased expression of genes related to EMT in AR-positive cell lines and the subset of adenocarcinoma mCRPC (Figure 6C, 6D, Reviewer 1 comment 1, discussed in Results, p. 7 and Discussion, p. 8). We considered performing the xenograft experiments; however, these experiments would require 8-12 months to perform, we believe that these experiments will not change the interpretation of the revised manuscript.</p><p>These new experiments together support the role of TBX3 and NFIC in CREB5-driven models and indicate that CREB5 plays a role in regulating EMT genes in AR-positive cells.</p><disp-quote content-type="editor-comment"><p>3. Figure 4A plots the dependency results in prostate cancer cell lines from Project Achilles, noting that TBX3 and NFIC both score. Are all of these lines AR-positive? What about widely used AR-negative lines like PC3 and DU145? Also, how do TBX3 and NFIC score in a pan cancer analysis? And what are the results from DepMap?</p></disp-quote><p>We agree that the dependency data from Depmap was not partitioned to exhibit the effects of TBX3 and NFIC in each cell line or on AR-positive (LNCaP, 22Rv1, MDAPC2B, VCAP – now Figure 4A, left) or AR-negative (PC3, DU145, NCIH660 – now Figure 4A, right, discussed in Results, p. 6) cell models. In the revised manuscript, we have now examined the overall average dependency of TBX3 and NFIC in all the AR-positive and –negative cell lines as compared to AR and FOXA1, the pan prostate cancer cell dependency (Pomerantz et al., Nat Genet, 2015) (Figure 4A). We also present ranking and percentile of these average dependencies with respect to all genes that were screened (now Figure 4B, discussed in Results, p. 6). We found that in AR-positive cell lines, TBX3 and NFIC exhibited a similar level of dependency as observed for FOXA1. When examining AR-negative cell lines in a similar fashion, we found that TBX3 was not required for cell fitness in these cell lines, while NFIC exhibited modest dependency as compared to FOXA1. These observations support the conclusion that TBX3 and NFIC regulate prostate cancer cell viability in the AR-setting (discussed in the response to Reviewer 1, comment 2).</p><p>When we compared the dependency profile of TBX3 and NFIC in 495 non-prostate cancer cell lines, we found that TBX3 and NFIC exhibited a pattern and degree of dependency similar to what we observed for AR and FOXA1 (now Figure 4B, discussed in Results, p. 6). These findings support the notion that TBX3 and NFIC are necessary for the fitness of AR-expressing prostate cancer models.</p><disp-quote content-type="editor-comment"><p>4. In figure 3D, LDB1 and DNMT1 are another two proteins that have reduced binding with CREB5 mutants comparing with wildtype CREB5. The authors ignored these two proteins and focused on NFIC and TBX3. Why not examine all four? Do LDB1 and DNMT1 also play a role in ART resistance?</p></disp-quote><p>In the updated manuscript, we indeed presented genomic, epigenomic, functional dependency, and clinical analyses on TBX3 and NFIC with respect to FOXA1 (Figure 4E, Figure 5A, B, C, discussed in Results, p. 6, p. 7).</p><p>As part of this revision, we compared DNMT1 and LDB1 to TBX3 and NFIC (<xref ref-type="table" rid="sa2table1">Author response table 1</xref>). In RIME experiments targeting CREB5 or FOXA1 in enzalutamide cultures, we found TBX3 and NFIC interacted with CREB5 and FOXA1 strongly while we found less robust interactions with DNMT1 and LDB1 based on unique peptide counts (First two columns of Revision Table 1, also in Supplementary File 1, Table 3). In addition, TBX3 and NFIC expression also showed a stronger correlation with FOXA1 in 209 mCRPC samples (3<sup>rd</sup> column in <xref ref-type="table" rid="sa2table1">Author response table 1</xref>). In the functional dependency data (4<sup>th</sup> to 6<sup>th</sup> columns in <xref ref-type="table" rid="sa2table1">Author response table 1</xref>), the average DEMETER scores of TBX3 and NFIC ranked greater than the 99<sup>th</sup> percentile in AR-positive PC cell lines. In the 495 non-PC cell lines, TBX3 and NFIC were less than the 1<sup>st</sup> percentile. In contrast, we found that DNMT1 and LDB1 did not exhibit this same pattern of dependency. For these reasons, while DNMT1 and LDB1 also interacted with FOXA1 and CREB5, our subsequent analyses and experiments focused on TBX3 and NFIC. We clarified these findings in the text of the revised manuscript (Results, p. 6, p. 7).</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><caption><title>Results from RIME, transcript association analyses, Dependency analyses are presented for TBX3, NFIC, DNMT1 and LDB1.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Unique Peptide Counts, CREBS RIME</th><th align="left" valign="bottom">Unique Peptide Counts, FOXA1 RIME</th><th align="left" valign="bottom">mCRPC Transcript Correlation with FOXA1</th><th align="left" valign="bottom">Dependency in AR-positive PC, Percentile</th><th align="left" valign="bottom">Dependency in AR-negative PC, Percentile</th><th align="left" valign="bottom">Overall Dependency, Percentile</th></tr></thead><tbody><tr><td align="left" valign="bottom">TBX3</td><td align="char" char="." valign="bottom">3.00</td><td align="char" char="." valign="bottom">6.50</td><td align="char" char="." valign="bottom">0.54</td><td align="char" char="." valign="bottom">99.78</td><td align="char" char="." valign="bottom">23.27</td><td align="char" char="." valign="bottom">0.19</td></tr><tr><td align="left" valign="bottom">NFIC</td><td align="char" char="." valign="bottom">4.00</td><td align="char" char="." valign="bottom">4.00</td><td align="char" char="." valign="bottom">0.42</td><td align="char" char="." valign="bottom">96.38</td><td align="char" char="." valign="bottom">85.22</td><td align="char" char="." valign="bottom">0.82</td></tr><tr><td align="left" valign="bottom">DNMT1</td><td align="char" char="." valign="bottom">2.00</td><td align="char" char="." valign="bottom">0.50</td><td align="char" char="." valign="bottom">-0.09</td><td align="char" char="." valign="bottom">28.25</td><td align="char" char="." valign="bottom">60.21</td><td align="char" char="." valign="bottom">63.38</td></tr><tr><td align="left" valign="bottom">LBD1</td><td align="char" char="." valign="bottom">2.00</td><td align="char" char="." valign="bottom">1.50</td><td align="char" char="." valign="bottom">0.07</td><td align="char" char="." valign="bottom">14.42</td><td align="char" char="." valign="bottom">65.56</td><td align="char" char="." valign="bottom">85.23</td></tr></tbody></table></table-wrap><p><xref ref-type="table" rid="sa2table1">Author response table 1</xref> is not included in the manuscript; however, we have clarified the rationale for studying TBX3 and NFIC in the revised manuscript (Results, p. 6, p. 7).</p><disp-quote content-type="editor-comment"><p>5. For the CREB5 binding proteins identified using RIME, especially the ART reprogrammed protein-protein interactions, the results would be more convincing if the authors could provide a few validations using co-immunoprecipitation (co-IP).</p></disp-quote><p>We agree with the Reviewer. We have attempted co-immunoprecipitation experiments with CREB5 to examine interaction with TBX3 and NFIC. The initial results are promising, in that we could detect a faint band that migrated at the predicted molecular weight for TBX3 and NFIC in the V5-CREB5 immune complexes as compared to an IgG control (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>, left). However, we concluded that the current commercially available TBX3 and NFIC antibodies are not sufficient to perform co-IPs of sufficient quality to conclude that these interactions are robust.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>Left.</title><p>V5-tagged CREB5 was targeted for immunoprecipitation in cell lysates in vehicle control (DMSO) or enzalutamide treated (ENZ) LNCaP cells. TBX3 and NFIC were detected in the total lysate (input) and precipitates (IP) using immunoblots. IgG was used as a negative precipitation control. Right. FOXA1 was targeted in enzalutamide treated cells in a Co-IP experiment. CREB5 and FOXA1 were detected in the total lysate (input) and precipitates (IP) using immunoblots. IgG was used as a negative precipitation control.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-sa2-fig2-v2.tif"/></fig><p>To test the other central hypothesis that CREB5 and FOXA1 are co-factors, we conducted co-IP experiments and found that CREB5 interacted with FOXA1 (<xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>, right). This finding supports the observation in that CREB5 and FOXA1 interactions with additional co-factors were similar in RIME, and they bound to similar transcription regulatory sites (Figure 2).</p><p>We have presented <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref> for the Reviewer’s use but given the question about the quality of the antibodies have not included this in the revised manuscripts.</p><disp-quote content-type="editor-comment"><p>6. In my opinion, the title &quot;CREB5 reprograms nuclear interactions to promote resistance to androgen receptor targeting therapies&quot; seems a bit misleading. The experiments and analysis focus on the effects of CREB5 in the presence of ART, which is already known to have a major impact on protein interactions and chromatin landscape.</p></disp-quote><p>In agreement with the reviewer, we recognize that several paths can lead to reprogramming. To increase the specificity in the title, we highlighted the CREB5 and FOXA1 interactions with the following proposed title for the revised manuscript (in Title, p.1):“</p><p>CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor targeting therapies&quot;</p><disp-quote content-type="editor-comment"><p>The work needs to clarify whether the effects of CREB5 overexpression and the dependencies on TBX3 and NIFC are restricted to AR-positive/AR-dependent models.</p></disp-quote><p>We have examined this based on experiments proposed in the response to Reviewer 1 comment 2 and comment 3 (Public Reviews).</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>This reviewer acknowledges the tremendous effort that went into producing high-quality OMIC data. The authors were likely unaware that CREB5 was an AR target gene and if they confirm it to be so in their model system they will have to reformulate their hypothesis and completely rewrite the paper. Further, there are no data presented in this paper that shows that CREB5 is causally involved in processes that confer resistance to enzalutamide. They need to validate he results of the OMICs approaches with such studies.</p></disp-quote><p>We thank the reviewer for their review of our manuscript.</p><p>We agree that showing that CREB5 drives enzalutamide resistance is critical. Specifically, we previously demonstrated (Hwang et al., Cell Rep, 2019) that CREB5 overexpression directly promoted resistance to enzalutamide in LNCaP cells. We also showed that CREB5 was overexpressed in an enzalutamide resistant, mCRPC patient-derived organoid and that suppression of CREB5 expression induced cell death in a prostate-patient derived organoid model. These findings are in consonance with the clinical observations in which CREB5 is amplified or overexpressed in a subset of mCRPC. Together, these experiments provide strong evidence that CREB5 indeed drives resistance to enzalutamide.</p><disp-quote content-type="editor-comment"><p>1. The apparent goal of the ORF screen (described in figure 1) was to identify factors whose involvement in PCa pathobiology was dependent on ENZ. However, a quick review of several published RNAseq datasets indicates that CREB5 is highly downregulated in PCa cells (normal and malignant) treated with R1881, Enz or Bicalutamide (its also downregulated by agonist activated progesterone receptor in several systems). Have the authors considered that they may have identified a gene (CREB5) that is AR repressed that is important for AR action and that the protein is not specifically related to ENZ/ADT resistance but is required for AR action? The potential involvement of CREB in AR action more broadly needs to be probed, but this reviewer suspects that when explored further the authors will find that the protein is not involved in resistance-dependent reprogramming of the AR cistrome per se.</p></disp-quote><p>We appreciate that the reviewer used different datasets than those that were used in this manuscript to conclude that CREB5 expression may be regulated by AR. We were surprised by this comment and have taken further analyses to further explore our original observations. As detailed below, we have confirmed that AR and CREB5 expression are independent in primary prostate and mCRPC.</p><p>Specifically, we previously queried the SU2C/PCF dataset (Abida et al., Proc Natl Acad Sci U S A, 2019) and found that CREB5 expression was independent of AR expression (Pearson correlation = 0.03) in mCRPC (Hwang et al., Cell Rep, 2019). In the same analyses, the AR target genes KLK2 and KLK3 are positively correlated with one another (R=0.82). We have now further evaluated CREB5 expression as a function of AR in both primary prostate cancer and mCRPC in data publicly available on cBioPortal. As summarized in <xref ref-type="table" rid="sa2table2">Author response table 2</xref>, we found that CREB5 and AR expression are independent of each other in each of these datasets. In comparison, we also analyzed the correlation of AR and FOXA1 expression, which exhibited a strong correlation as expected (Pomerantz et al., Nat Genet, 2015, Pomerantz et al., Nat Genet, 2020). Together, these analyses indicate that CREB5 expression is not primarily regulated by AR in these widely used tumor datasets. However, as Reviewer 2 indicated, we surmise that it remains possible that in specific models and conditions, AR may suppress CREB5 transcripts.</p><table-wrap id="sa2table2" position="float"><label>Author response table 2.</label><caption><title>Transcription data from three independent studies were examined.</title><p>Pearson correlations were performed to examine the associations between CREB5 and AR as well as AR and FOXA1. The cohort features are described along with the correlation value and p-value. The p-values were are marked as significant (**) or not significant (n.s.) based on type I error levels at less than 0.05.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="bottom"/><th align="left" colspan="2" valign="bottom">CREB5, AR</th><th align="left" colspan="2" valign="bottom">AR, FOXA1</th></tr><tr><th align="left" valign="bottom">R</th><th align="left" valign="bottom">p-val</th><th align="left" valign="bottom">R</th><th align="left" valign="bottom">p-val</th></tr></thead><tbody><tr><td align="left" valign="bottom">PCF/SU2C (n=266, mCRPC only) (Abida et al., Proc Natl Acad Sci USA, 2019)</td><td align="char" char="." valign="bottom">-0.11</td><td align="char" char="." valign="bottom">0.0612 (n.s.)</td><td align="char" char="." valign="bottom">0.41</td><td align="char" char="hyphen" valign="bottom">3.70E-12**</td></tr><tr><td align="left" valign="bottom">TCGA PRAD (n=488, Primary only)</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="." valign="bottom">0.0707 (n.s.)</td><td align="char" char="." valign="bottom">0.37</td><td align="char" char="hyphen" valign="bottom">2.29E-17**</td></tr><tr><td align="left" valign="bottom">MSK (n=128, primary and mCRPC) (Taylor et al., Cancer Cell, 2010)</td><td align="char" char="." valign="bottom">0.08</td><td align="char" char="." valign="bottom">0.34 (n.s.)</td><td align="char" char="." valign="bottom">0.4</td><td align="char" char="hyphen" valign="bottom">2.92E-06**</td></tr></tbody></table></table-wrap><p>We have provided <xref ref-type="table" rid="sa2table2">Author response table 2</xref> for the editors and reviewers to use but have not included this Table in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>2. Given that CREB5 is highly downregulated in cells treated with R1881, Enz or Bicalutamide one interpretation of the authors findings is that overexpression of CREB5 bypasses this regulatory pathway but that should impact the activity of both agonists and antagonists. Thus, the authors need to consider that they may have identified a gene (CREB5) that is AR repressed that its reduced expression is important for AR action and that dysregulation of the expression of this protein is not specifically related to ENZ/ADT resistance? To support their specific hypothesis the authors would have to show that CREB5 overexpression has no effect on R1881 dependent transcription. Otherwise the focus of the paper must change completely to consider a more &quot;physiological&quot; role for CREB5 in AR action.</p></disp-quote><p>We refer the Reviewer to consider the correlation of AR activity and CREB5 expression in mCRPC in the response to Reviewer 2, comment 1. We found that the relationship between CREB5 and AR expression was independent in prostate tumors.</p><p>The Reviewer suggests that CREB5 may play a role in responses to both AR agonists and antagonists. In our prior work, we found that CREB5 regulated general AR transcription targets, which would also be regulated by R1881 based on a qRT-PCR panel of AR target genes (Hwang et al., Cell Rep, 2019). However, in this manuscript we showed that CREB5 expression had a modest anti-proliferative effect in ORF screens conducted in cultures with full serum, which represents cultures in which androgens are in excess (Figure 1, discussed in Results, p. 7). In contrast, we found that CREB5 was the top candidate out of 17,255 ORFs when cells were treated with enzalutamide and androgen deprivation. As R1881 is an androgen analog, we predict that CREB5 would not have significant pro-proliferative phenotypes.</p><p>Due to the significant phenotype we observed with androgen receptor inhibitors, we focused on the mechanistic characterization of CREB5 in cells and tumor samples that have received some form of AR signaling inhibition. We have also updated the title of this study to reflect this emphasis (Reviewer 1, comment 6).</p><p>We also note that we previously reported that CREB5 is genomically amplified with limited deletion events in mCRPC (only one observed), in which samples are derived from patients treated with ART. We re-examined the data as part of this revision and presented the updates here (Author response image 3). These results support that prostate tumors, which are AR-positive, select for increases in CREB5 expression.</p><p><xref ref-type="fig" rid="sa2fig3">Author response image 3</xref> is based on re-analyses of published studies and thus not included in the revised manuscript.</p><fig id="sa2fig3" position="float"><label>Author response image 3.</label><caption><title>CREB5 amplifications (red) and deletions (blue) are examined and displayed across prostate cancer cohorts as of 12.2.2021.</title><p>In total, there were variable amplification rates and we only detected one homozygous deletion in a primary prostate tumor in the 2018 study that included 680 primary prostate cancer samples and 333 mCRPC. Adapted from cBioportal.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-73223-sa2-fig3-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>3. The appearance of FOXA1 GRHL2, FOXA1 et at CREB5 binding sites is interesting but the requirement for AR in these studies is not demonstrated.</p></disp-quote><p>We have previously reported that suppressing FOXA1 or AR expression by RNAi in CREB5 overexpressing LNCaP cell lines induced cell death (Hwang et al., Cell Rep, 2019). This observation supports the conclusion that CREB5 requires AR and the key co-factor FOXA1 in the CREB5-mediated enzalutamide resistant phenotype. We have also repeated this observation as part of this response (Supplementary Figure 1). To make the title more specific, we have changed the title of the revised manuscript to highlight CREB5 as a co-factor to FOXA1 (Reviewer 1, comment 6, updated in Title, p. 1), which better represents this work.</p><p>While GRHL2 is also a key AR co-factor, we believe that the RNAi experiments targeting AR or FOXA1 demonstrate that AR and the key AR co-factor FOXA1 are necessary in CREB5 overexpressing cells.</p><disp-quote content-type="editor-comment"><p>4. In designing the screen the assumption is made that CSS is just FBS &quot;without androgens&quot; which is not the case. FBS +/- enz would seem to be a more relevant model to look for important mediators of resistance (enz is not very active in this scenario but that is another story!). Further, if androgens suppress CREB5 (as has been demonstrated) and this is required for proliferation then overexpression of CREB5 would bypass this regulation and thus would explain the results observed in FBS (inhibition of proliferation).</p></disp-quote><p>We agree with this comment and have clarified how experiments after the ORF screen were conducted with enzalutamide in FBS (discussed in Materials and methods, p. 9).</p><p>Materials and methods, Page 9. “We analyzed a published genome-scale ORF screen performed in LNCaP cells (Hwang et al., 2019). Specifically, we compared the experimental arms conducted in control media (FCS) with androgens and androgen stripped media (CSS) containing enzalutamide. Z-scores represent the relative effects of each ORF on cell proliferation after 25 days in culture.”</p><p>While the screen was conducted in CSS and enzalutamide, in which we describe as experimental conditions of ADT/ART (Figure 1A, discussed in Results, p. 3. p. 4), all following –omic experiments in this study were performed in FBS and enzalutamide, as we have not indicated otherwise. In the control experiments in which no enzalutamide was added, we used FBS and not CSS. We thank the Reviewer for this suggestion.</p><disp-quote content-type="editor-comment"><p>5. If CREB5 downregulation is required for normal AR function then it is hard to explain the dependencies highlighted in DEPMAP. Unless its overexpression prevents the repression/downregulation of proliferation that occurs in PCa cancer cells as androgen levels rise.</p></disp-quote><p>See the response to Reviewer 2, comment 1 and 2 in which we observed that human tumors independently expressed CREB5 and AR.</p><p>References</p><p>Abida, W., J. Cyrta, G. Heller, D. Prandi, J. Armenia, I. Coleman, M. Cieslik, M. Benelli, D. Robinson, E. M. Van Allen, A. Sboner, T. Fedrizzi, J. M. Mosquera, B. D. Robinson, N. De Sarkar, L. P. Kunju, S. Tomlins, Y. M. Wu, D. Nava Rodrigues, M. Loda, A. Gopalan, V. E. Reuter, C. C. Pritchard, J. Mateo, D. Bianchini, S. Miranda, S. Carreira, P. Rescigno, J. Filipenko, J. Vinson, R. B. Montgomery, H. Beltran, E. I. Heath, H. I. Scher, P. W. Kantoff, M. E. Taplin, N. Schultz, J. S. deBono, F. Demichelis, P. S. Nelson, M. A. Rubin, A. M. Chinnaiyan and C. L. Sawyers (2019). &quot;Genomic correlates of clinical outcome in advanced prostate cancer.&quot; Proc Natl Acad Sci U S A 116(23): 11428-11436.</p><p>Alumkal, J. J., D. Sun, E. Lu, T. M. Beer, G. V. Thomas, E. Latour, R. Aggarwal, J. Cetnar, C. J. Ryan, S. Tabatabaei, S. Bailey, C. B. Turina, D. A. Quigley, X. Guan, A. Foye, J. F. Youngren, J. Urrutia, J. Huang, A. S. Weinstein, V. Friedl, M. Rettig, R. E. Reiter, D. E. Spratt, M. Gleave, C. P. Evans, J. M. Stuart, Y. Chen, F. Y. Feng, E. J. Small, O. N. Witte and Z. Xia (2020). &quot;Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.&quot; Proc Natl Acad Sci U S A 117(22): 12315-12323.</p><p>Beltran, H., D. Prandi, J. M. Mosquera, M. Benelli, L. Puca, J. Cyrta, C. Marotz, E. Giannopoulou, B. V. Chakravarthi, S. Varambally, S. A. Tomlins, D. M. Nanus, S. T. Tagawa, E. M. Van Allen, O. Elemento, A. Sboner, L. A. Garraway, M. A. Rubin and F. Demichelis (2016). &quot;Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.&quot; Nat Med 22(3): 298-305.</p><p>He, M. X., M. S. Cuoco, J. Crowdis, A. Bosma-Moody, Z. Zhang, K. Bi, A. Kanodia, M. J. Su, S. Y. Ku, M. M. Garcia, A. R. Sweet, C. Rodman, L. DelloStritto, R. Silver, J. Steinharter, P. Shah, B. Izar, N. C. Walk, K. P. Burke, Z. Bakouny, A. K. Tewari, D. Liu, S. Y. Camp, N. I. Vokes, K. Salari, J. Park, S. Vigneau, L. Fong, J. W. Russo, X. Yuan, S. P. Balk, H. Beltran, O. Rozenblatt-Rosen, A. Regev, A. Rotem, M. E. Taplin and E. M. Van Allen (2021). &quot;Transcriptional mediators of treatment resistance in lethal prostate cancer.&quot; Nat Med 27(3): 426-433.</p><p>Hwang, J. H., J. H. Seo, M. L. Beshiri, S. Wankowicz, D. Liu, A. Cheung, J. Li, X. Qiu, A. L. Hong, G. Botta, L. Golumb, C. Richter, J. So, G. J. Sandoval, A. O. Giacomelli, S. H. Ly, C. Han, C. Dai, H. Pakula, A. Sheahan, F. Piccioni, O. Gjoerup, M. Loda, A. G. Sowalsky, L. Ellis, H. Long, D. E. Root, K. Kelly, E. M. Van Allen, M. L. Freedman, A. D. Choudhury and W. C. Hahn (2019). &quot;CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.&quot; Cell Rep 29(8): 2355-2370 e2356.</p><p>Kregel, S., J. L. Chen, W. Tom, V. Krishnan, J. Kach, H. Brechka, T. B. Fessenden, M. Isikbay, G. P. Paner, R. Z. Szmulewitz and D. J. Vander Griend (2016). &quot;Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.&quot; Oncotarget 7(18): 26259-26274.</p><p>Pomerantz, M. M., F. Li, D. Y. Takeda, R. Lenci, A. Chonkar, M. Chabot, P. Cejas, F. Vazquez, J. Cook, R. A. Shivdasani, M. Bowden, R. Lis, W. C. Hahn, P. W. Kantoff, M. Brown, M. Loda, H. W. Long and M. L. Freedman (2015). &quot;The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.&quot; Nat Genet 47(11): 1346-1351.</p><p>Pomerantz, M. M., X. Qiu, Y. Zhu, D. Y. Takeda, W. Pan, S. C. Baca, A. Gusev, K. D. Korthauer, T. M. Severson, G. Ha, S. R. Viswanathan, J. H. Seo, H. M. Nguyen, B. Zhang, B. Pasaniuc, C. Giambartolomei, S. A. Alaiwi, C. A. Bell, E. P. O'Connor, M. S. Chabot, D. R. Stillman, R. Lis, A. Font-Tello, L. Li, P. Cejas, A. M. Bergman, J. Sanders, H. G. van der Poel, S. A. Gayther, K. Lawrenson, M. A. S. Fonseca, J. Reddy, R. I. Corona, G. Martovetsky, B. Egan, T. Choueiri, L. Ellis, I. P. Garraway, G. M. Lee, E. Corey, H. W. Long, W. Zwart and M. L. Freedman (2020). &quot;Prostate cancer reactivates developmental epigenomic programs during metastatic progression.&quot; Nat Genet 52(8): 790-799.</p><p>Taylor, B. S., N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B. S. Carver, V. K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J. E. Major, M. Wilson, N. D. Socci, A. E. Lash, A. Heguy, J. A. Eastham, H. I. Scher, V. E. Reuter, P. T. Scardino, C. Sander, C. L. Sawyers and W. L. Gerald (2010). &quot;Integrative genomic profiling of human prostate cancer.&quot; Cancer Cell 18(1): 11-22.</p></body></sub-article></article>